<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease - Ng, L - 2017 | Cochrane Library</title> <meta content="Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease - Ng, L - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011776.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease - Ng, L - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011776.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011776.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease" name="citation_title"/> <meta content="Louisa Ng" name="citation_author"/> <meta content="Royal Melbourne Hospital, Royal Park Campus" name="citation_author_institution"/> <meta content="louisa.ng@mh.org.au" name="citation_author_email"/> <meta content="Fary Khan" name="citation_author"/> <meta content="Carolyn A Young" name="citation_author"/> <meta content="The Walton Centre NHS Foundation Trust" name="citation_author_institution"/> <meta content="Mary Galea" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD011776.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/01/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011776.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011776.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011776.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amyotrophic Lateral Sclerosis [*complications]; Enteral Nutrition; Exercise Therapy; Motor Neuron Disease [complications]; Muscle Cramp [*drug therapy, etiology]; Muscle Spasticity [etiology, *therapy]; Noninvasive Ventilation; Pain [*drug therapy, etiology]; Respiratory Insufficiency [etiology, *therapy]; Review Literature as Topic; Sialorrhea [etiology, *therapy]; Transcranial Magnetic Stimulation" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011776.pub2&amp;doi=10.1002/14651858.CD011776.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="SVRJ5zHF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011776\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011776\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011776.pub2",title:"Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease",firstPublishedDate:"Jan 10, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=SVRJ5zHF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011776.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011776.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011776.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011776.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011776.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011776.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011776.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011776.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011776.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011776.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11033 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011776.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-sec-0072"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-sec-0036"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-sec-0051"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/appendices#CD011776-sec-0087"> Search strategies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Overview</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information#CD011776-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Louisa Ng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information#CD011776-cr-0003">Fary Khan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information#CD011776-cr-0004">Carolyn A Young</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information#CD011776-cr-0005">Mary Galea</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information/en#CD011776-sec-0090">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 January 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011776.pub2">https://doi.org/10.1002/14651858.CD011776.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011776-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011776-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011776-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011776-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011776-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011776-abs-0001" lang="en"> <section id="CD011776-sec-0001"> <h3 class="title" id="CD011776-sec-0001">Background</h3> <p>Motor neuron disease (MND), which is also known as amyotrophic lateral sclerosis (ALS), causes a wide range of symptoms but the evidence base for the effectiveness of the symptomatic treatment therapies is limited. </p> </section> <section id="CD011776-sec-0002"> <h3 class="title" id="CD011776-sec-0002">Objectives</h3> <p>To summarise the evidence from Cochrane Systematic Reviews of all symptomatic treatments for MND. </p> </section> <section id="CD011776-sec-0003"> <h3 class="title" id="CD011776-sec-0003">Methods</h3> <p>We searched the <i>Cochrane Database of Systematic Reviews</i> (CDSR) on 15 November 2016 for systematic reviews of symptomatic treatments for MND. We assessed the methodological quality of the included reviews using the Assessment of Multiple Systematic Reviews (AMSTAR) tool and the GRADE approach. We followed standard Cochrane study (review) selection and data extraction procedures. We reported findings narratively and in tables. </p> </section> <section id="CD011776-sec-0004"> <h3 class="title" id="CD011776-sec-0004">Main results</h3> <p>We included nine Cochrane Systematic Reviews of interventions to treat symptoms in people with MND. Three were empty reviews with no included randomised controlled trials (RCTs); however, all three reported on non‐RCT evidence and the remaining six included mostly one or two studies. We deemed all of the included reviews of high methodological quality. </p> <p><b>Drug therapy for pain</b> </p> <p>There is no RCT evidence in a Cochrane Systematic Review exploring the efficacy of drug therapy for pain in MND. </p> <p><b>Treatment for cramps</b> </p> <p>There is evidence (13 RCTs, N = 4012) that for the treatment of cramps in MND, compared to placebo: </p> <p>– memantine and tetrahydrocannabinol (THC) are probably ineffective (moderate‐quality evidence); </p> <p>– vitamin E may have little or no effect (low‐quality evidence); and</p> <p>– the effects of L‐threonine, gabapentin, xaliproden, riluzole, and baclofen are uncertain as the evidence is either very low quality or the trial specified the outcome but did not report numerical data. </p> <p>The review reported adverse effects of riluzole, but it is not clear whether other interventions had adverse effects. </p> <p><b>Treatment for spasticity</b> </p> <p>It is uncertain whether an endurance‐based exercise programme improved spasticity or quality of life, measured at three months after the programme, as the quality of evidence is very low (1 RCT, comparison "usual activities", N = 25). The review did not evaluate other approaches, such as use of baclofen as no RCTs were available. </p> <p><b>Mechanical ventilation for supporting respiratory function</b> </p> <p>Non‐invasive ventilation (NIV) probably improves median survival and quality of life in people with respiratory insufficiency and normal to moderately impaired bulbar function compared to standard care, and improves quality of life but not survival for people with poor bulbar function (1 RCT, N = 41, moderate‐quality evidence; a second RCT did not provide data). The review did not evaluate other approaches such as tracheostomy‐assisted ('invasive') ventilation, or assess timing of NIV initiation. </p> <p><b>Treatment for sialorrhoea</b> </p> <p>A single session of botulinum toxin type B injections to parotid and submandibular glands probably improves sialorrhoea and quality of life at up to 4 weeks compared to placebo injections, but not at 8 or 12 weeks after the injections (moderate‐quality evidence from 1 placebo‐controlled RCT, N = 20). The review authors found no trials of other approaches. </p> <p><b>Enteral tube feeding for supporting nutrition</b> </p> <p>There is no RCT evidence in a Cochrane Systematic Review to support benefit or harms of enteral tube feeding in supporting nutrition in MND. </p> <p><b>Repetitive transcranial magnetic stimulation</b> </p> <p>It is uncertain whether repetitive transcranial magnetic stimulation (rTMS) improves disability or limitation in activity in MND in comparison with sham rTMS (3 RCTs, very low quality evidence, N = 50). </p> <p><b>Therapeutic exercise</b> </p> <p>There is evidence that exercise may improve disability in MND at three months after the exercise programme, but not quality of life, in comparison with "usual activities" or "usual care" including stretching (2 RCTs, low‐quality evidence, N = 43). </p> <p><b>Multidisciplinary care</b> </p> <p>There is no RCT evidence in a Cochrane Systematic Review to demonstrate any benefit or harm for multidisciplinary care in MND. </p> <p>None of the reviews, other than the review of treatment for cramps, reported that adverse events occurred. However, the trials were too small for reliable adverse event reporting. </p> </section> <section id="CD011776-sec-0005"> <h3 class="title" id="CD011776-sec-0005">Authors' conclusions</h3> <p>This overview has highlighted the lack of robust evidence in Cochrane Systematic Reviews on interventions to manage symptoms resulting from MND. It is important to recognise that clinical trials may fail to demonstrate efficacy of an intervention for reasons other than a true lack of efficacy, for example because of insufficient statistical power, the wrong choice of dose, insensitive outcome measures or inappropriate participant eligibility. The trials were mostly too small to reliably assess adverse effects of the treatments. The nature of MND makes it difficult to research clinically accepted or recommended practice, regardless of the level of evidence supporting the practice. It would not be ethical, for example, to design a placebo‐controlled trial for treatment of pain in MND or to withhold multidisciplinary care where such care is available. It is therefore highly unlikely that there will ever be classically designed placebo‐controlled RCTs in these areas. </p> <p>We need more research with appropriate study designs, robust methodology, and of sufficient duration to address the changing needs—of people with MND and their caregivers—associated with MND disease progression and mortality. There is a significant gap in studies assessing the effectiveness of interventions for symptoms relating to MND, such as pseudobulbar emotional lability and cognitive and behavioural difficulties. Future studies should use appropriate outcome measures that are reliable, have internal and external validity, and are sensitive to change in what is being measured (such as quality of life). </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011776-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011776-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011776-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011776-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011776-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011776-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011776-abs-0004" lang="en"> <h3>Managing symptoms in motor neuron disease</h3> <p><b>Review question</b> </p> <p>What are the effects of treatments for managing symptoms in motor neuron disease (MND)?</p> <p><b>Background</b> </p> <p>Motor neuron disease (MND), which is also known as amyotrophic lateral sclerosis (ALS), is an uncommon, incurable disease that affects the nerves involved in movement. MND gets worse over time and affects muscles of the limbs, speech, swallowing and breathing. People with MND experience a wide range of symptoms, including a number of physical ability limitations, pain, spasticity, cramps, swallowing problems and difficulty breathing. It is important to recognise that clinical trials may fail to show that a treatment is effective for several reasons that are not related to the effects of the treatment itself, for example when there are too few people in a trial, or investigators choose an ineffective dose of a drug. </p> <p><b>Review characteristics</b> </p> <p>We searched for Cochrane Systematic Reviews of treatments aiming to manage symptoms of MND. We found nine reviews that fitted the objectives of this study. These reviewed randomized controlled trials (RCTs) of treatments for pain, cramps, spasticity, and sialorrhoea, and assessed the effects of mechanical ventilation (non‐invasive ventilation), enteral tube feeding, repetitive transcranial magnetic stimulation (rTMS), therapeutic exercise, and multidisciplinary care. The trials compared the treatment with an inactive treatment (placebo drug or sham therapy) or usual care. </p> <p><b>Key results and quality of the evidence</b> </p> <p>There are currently many treatments in clinical use for pain, but no robust information currently exists on their effectiveness in people with MND. </p> <p>There is evidence that memantine and tetrahydrocannabinol are probably ineffective for cramps in ALS and that vitamin E may be ineffective. There is too little information from RCTs on the effects of other treatments studied, including L‐threonine, gabapentin, xaliproden, riluzole, and baclofen. The review did not report adverse events other than for riluzole. </p> <p>It is uncertain whether exercise improves muscle stiffness (spasticity). Exercise may improve disability; it may not improve quality of life. Other interventions for spasticity have not been studied in RCTs. </p> <p>Non‐invasive mechanical ventilation probably improves survival and quality of life in ALS; it may not improve survival in people with poor bulbar function. The review did not assess when to start NIV. </p> <p>A single session of botulinum toxin injections into the salivary glands probably improves excessive saliva production and dribbling, and quality of life in the short term (over weeks but not months). </p> <p>At present, there is no evidence available from controlled trials to indicate whether or not there is a benefit to tube feeding for supporting nutrition, nor is there any evidence to indicate whether multidisciplinary care is helpful or harmful. It is uncertain whether rTMS is of benefit for improving disability or activity limitation in MND. Lack of evidence on multidisciplinary care or other treatments, however, should not be interpreted as ineffectiveness. </p> <p>Only the cramps review reported that adverse events occurred. The trials were mostly too small to reliably assess adverse events or rule out uncommon events. </p> <p>More research is required to determine which treatments help to manage symptoms for those living with MND, using suitable types of studies and outcome measures. </p> <p>This overview is up to date to November 2016.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011776-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011776-sec-0072"></div> <section id="CD011776-sec-0073"> <p> <h5 class="title">Implications for practice</h5> <section id="CD011776-sec-0074"> <p>The limitations of the evidence base mean that absence of proof for the following treatments <i>cannot</i> be interpreted as proof that they are ineffective. </p> <section id="CD011776-sec-0075"> <p><b>Drug therapy for pain</b></p> <p>Pain is a common unresolved problem in motor neuron disease (MND) and in the absence of any evidence from randomised controlled trials (RCTs), treatment for pain in MND could follow the 1990 World Health Organization Analgesic Ladder (<a href="./references#CD011776-bbs2-0075" title="Cancer pain relief and palliative care. Report of a WHO Expert Committee1990; Vol. World Health Organization Technical Report Series, issue 804:1‐75. ">WHO 1990</a>). </p> </section> <section id="CD011776-sec-0076"> <p><b>Treatment for cramps</b></p> <p>Cramps can cause pain and impair function. There is some evidence of lack of efficacy for tetrahydrocannabinol, memantine and vitamin E for cramps in MND. Other drug treatments may work but have little or no evidence for or against their use. In the absence of any studies relating to physical therapy, such therapies might also be considered as a treatment option. </p> </section> <section id="CD011776-sec-0077"> <p><b>Treatment for spasticity</b></p> <p>It is uncertain whether an endurance‐based exercise programme may be useful for the treatment of spasticity as the evidence is of very low quality. In the absence of any RCTs relating to the current practice of a programme of regular stretching, and use of drugs such as baclofen, no statement can be made about efficacy based on any high‐quality study. </p> </section> <section id="CD011776-sec-0078"> <p><b>Mechanical ventilation for supporting respiratory function</b></p> <p>Non‐invasive ventilation probably has survival and QoL benefit in people with good or moderate bulbar function, and QoL benefit in people with poor bulbar function. </p> </section> <section id="CD011776-sec-0079"> <p><b>Treatment for sialorrhoea</b></p> <p>Botulinum toxin type B injections to parotid and submandibular glands are probably effective in the short term (up to 4 weeks). There is probably no benefit for sialorrhoea beyond this time after a single injection. </p> </section> <section id="CD011776-sec-0080"> <p><b>Enteral tube feeding for supporting nutrition</b></p> <p>There is an absence of any evidence from RCTs for or against the efficacy of percutaneous endoscopic gastrostomy (PEG) insertion for supporting nutrition. Non‐randomised and other study design publications provide a rationale for this intervention. </p> </section> <section id="CD011776-sec-0081"> <p><b>Interventions at the level of activity and participation</b></p> <section id="CD011776-sec-0082">Repetitive transcranial magnetic stimulation <p>It is uncertain whether rTMS improves disability.</p> </section> <section id="CD011776-sec-0083">Therapeutic exercise <p>Exercise may improve disability in the short term (3 months).</p> </section> <section id="CD011776-sec-0084">Multidisciplinary care <p>There are no RCTs in this area. There is a clinical consensus that multidisciplinary care should be provided where available and this is reflected in the recently updated UK National Clinical Guideline Centre (NICE) recommendations (<a href="./references#CD011776-bbs2-0064" title="National Institute for Health and Care Excellence. Motor neurone disease: assessment and management. NICE guideline NG42. London: National Institute for Health and Clinical Excellence (UK)2016. [https://www.nice.org.uk/guidance/ng42/evidence/full‐guideline‐2361774637] ">NICE 2016</a>). The absence of proof that multidisciplinary care is effective must not be interpreted as proof that this approach is ineffective. </p> </section> </section> </section> </p> <p> <h5 class="title">Implications for research</h5> <section id="CD011776-sec-0085"> <p>This overview has highlighted a significant gap in the current literature. There is need for: </p> <p>1) appropriate study designs, robust methodology and longitudinal data which address the changing needs—of people with MND and their caregivers—associated with MND disease progression and mortality; </p> <p>2) studies to assess the:</p> <p> <ul id="CD011776-list-0043"> <li> <p>effectiveness of interventions on all symptoms relating to MND, including symptoms such as pseudobulbar lability and cognitive and behavioural difficulties; </p> </li> <li> <p>benefits of interventions on quality of life (QoL);</p> </li> <li> <p>effectiveness of specific interventions (and components), such as:</p> </li> </ul> <ul class="plain" id="CD011776-list-0044"> <li> <ul id="CD011776-list-0045"> <li> <p>physical therapy for the treatment of cramps;</p> </li> <li> <p>drug treatments and stretching for spasticity;</p> </li> <li> <p>type, intensity, frequency of interventions; and</p> </li> </ul> </li> </ul> <ul id="CD011776-list-0046"> <li> <p>the cost effectiveness of interventions;</p> </li> <li> <p>impact of interventions on people with MND and their families;</p> </li> <li> <p>other factors that affect outcomes (support, adaptive aids and equipment, end‐of‐life issues); </p> </li> </ul> </p> <p>3) the use of appropriate outcome measures including:</p> <p> <ul id="CD011776-list-0047"> <li> <p>reliable and valid outcome measures which reflect domains of the International Classification of Functioning, Disability and Health (ICF), are sensitive to what is being measured (such as QoL) and to end‐of‐life care needs; </p> </li> </ul> </p> <p>4) research into different phases of MND, hence covering the spectrum of care required for this population. </p> </section> </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011776-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011776-sec-0016"></div> <section id="CD011776-sec-0017"> <h3 class="title" id="CD011776-sec-0017">Description of the condition</h3> <p>Motor neuron disease (MND), which is also known as amyotrophic lateral sclerosis (ALS), is an uncommon, fatal neurodegenerative disorder of the motor system in adults. It has a reported population incidence of between 1.5 and 2.5 per 100,000 person‐years worldwide, with the only established risk factors being age and family history (<a href="./references#CD011776-bbs2-0071" title="TurnerMR , Al‐ChalabiA . Clinical phenotypes. In: KiernanM editor(s). The Motor Neurone Disease Handbook. Pyrmont: Australasian Medical Publishing Company Limited, 2007:56‐73. ">Turner 2007</a>), and possibly military deployment (<a href="./references#CD011776-bbs2-0032" title="BeardJD , EngelLS , RichardsonDB , GammonMD , BairdC , UmbachDM , et al. Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology. Environment International2016;91:104‐15. ">Beard 2016</a>). Several known genetic changes, such as the pathological hexanucleotide repeat expansion in C9ORF72 (<a href="./references#CD011776-bbs2-0046" title="DeJesus‐HernandezM , MackenzieIR , BoeveBF , BoxerAL , BakerM , RutherfordNJ , et al. Expanded GGGGCC hexanucleotide repeat in non‐coding region of C9ORF72 causes chromosome 9p‐linked frontotemporal dementia and amyotrophic lateral sclerosis. Neuron2011;72(2):245‐56. ">DeJesus‐Hernandez 2011</a>; <a href="./references#CD011776-bbs2-0065" title="RentonAE , MajounieE , WaiteA , Simón‐SánchezA , RollinsonS , GibbsJR , et al. A hexanucleotide repeat expansion in C9ORF72 Is the cause of chromosome 9p21‐linked ALS‐FTD. Neuron2011;72(2):257‐68. ">Renton 2011</a>), have been causally associated with familial and sporadic ALS. The disease occurs throughout adult life, with the peak incidence between 50 and 75 years of age, and is more common in men (in the ratio 3:2) (<a href="./references#CD011776-bbs2-0071" title="TurnerMR , Al‐ChalabiA . Clinical phenotypes. In: KiernanM editor(s). The Motor Neurone Disease Handbook. Pyrmont: Australasian Medical Publishing Company Limited, 2007:56‐73. ">Turner 2007</a>). Historically, ALS was identified as a clinical syndrome distinguishable from other motor neuron diseases such as primary lateral sclerosis, primary muscular atrophy, and progressive bulbar palsy, based upon the location of first symptom and the extent to which anterior horn cells or corticomotor neurons are initially involved. However, it is increasingly evident that ALS is clinically and pathophysiologically diverse, with clear overlap with frontotemporal dementia where there is early loss of frontotemporal system neurons (<a href="./references#CD011776-bbs2-0072" title="TurnerMR , HardimanO , BenatarM , BrooksBR , ChioA , deCarvalhoM , et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology2013;12(3):310‐22. ">Turner 2013</a>). Death (usually from respiratory failure) follows on average two to four years after onset, but some people with MND may survive for a decade or more (<a href="./references#CD011776-bbs2-0050" title="ForsgrenL , AlmayBG , HolmgrenG , WallS . Epidemiology of motor neuron disease in northern Sweden. Acta Neurologica Scandinavica1983;68(1):20‐9. ">Forsgren 1983</a>). </p> <p>Whilst the aetiology of MND is unknown, current evidence suggests that multiple interacting factors contribute to motor neuron injury in MND. The working hypothesis is that MND, like many other chronic diseases, is a complex genetic condition and the relative contribution of individual environmental and genetic factors is likely to be small (<a href="./references#CD011776-bbs2-0028" title="Al‐ChalabiA , HardimanO . The epidemiology of ALS: a conspiracy of genes, environment and time. Nature Reviews Neurology2013;9(11):617‐28. ">Al‐Chalabi 2013</a>). The three key pathogenetic hypotheses invoke genetic factors, oxidative stress and glutamatergic toxicity, which result in damage to critical target proteins, such as neurofilaments, and organelles such as mitochondria (<a href="./references#CD011776-bbs2-0040" title="BrownRHJr . Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell1995;80(5):687‐92. ">Brown 1995</a>; <a href="./references#CD011776-bbs2-0044" title="CooksonMR , ShawPJ . Oxidative stress and motor neurone disease. Brain Pathology1999;9(1):165‐86. ">Cookson 1999</a>; <a href="./references#CD011776-bbs2-0066" title="ShawPJ , IncePG . Glutamate, excitotoxicity and amyotrophic lateral sclerosis. Journal of Neurology1997;244(Suppl 2):S3‐14. ">Shaw 1997</a>). In addition, there is increasing evidence supporting the hypothesis that altered ribonucleic acid (RNA) processing and aggregation of abnormal proteins play a major role in the pathogenesis of MND (<a href="./references#CD011776-bbs2-0057" title="KimHJ , KimNC , WangYD , ScarboroughEA , MooreJ , DiazZ , et al. Mutations in prion‐like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature2013;495(7442):467‐73. ">Kim 2013</a>; <a href="./references#CD011776-bbs2-0073" title="VermaA , TandanR . RNA quality control and protein aggregates in amyotrophic lateral sclerosis: a review. Muscle &amp; Nerve2013;47(3):330‐8. ">Verma 2013</a>). </p> <p>The diagnosis of MND is clinical and includes the presence of upper motor neuron and lower motor neuron signs, progression of disease and the absence of an alternative explanation. There is no single diagnostic test at present that can confirm or entirely exclude the diagnosis of MND. Clinicians rely mainly on clinical history and examination, supported by electrodiagnostic studies (<a href="./references#CD011776-bbs2-0048" title="EisenA , SwashM . Clinical neurophysiology of ALS. Clinical Neurophysiology2001;112(12):2190‐201. ">Eisen 2001</a>), and negative findings in neuroimaging and laboratory studies. </p> <p>The symptoms in MND are diverse and challenging for both the person with MND and the clinician. They include weakness, spasticity, limitations in mobility and activities of daily living, communication deficits, dysphagia, respiratory compromise, fatigue, sleep disorders, pain and psychosocial distress. The International Classification of Functioning, Disability and Health (ICF) defines a common language for describing the impact of disease at different levels: impairment (body structure and function) and limitation in activity and participation (<a href="./references#CD011776-bbs2-0076" title="World Health Organization. International Classification of Functioning, Disability, and Health (ICF). International Classification of Functioning, Disability, and Health (ICF). Geneva: World Health Organization, 2001. ">WHO 2001</a>). Within this framework MND‐related impairments (weakness and spasticity), can limit ‘activity’ or function (mobility, self‐care) and ‘participation’ (driving, employment, family and social reintegration). ‘Contextual factors’ that may be environmental (extrinsic) or personal (intrinsic) interact with all the other constructs to shape the impact of MND on people with the condition and their families. </p> <p>The burden of disease and economic impact of MND upon people who have the condition, their caregivers (often family members) and on society is substantial (<a href="./references#CD011776-bbs2-0058" title="KleinLM , ForshewDA . The economic impact of ALS. Neurology1996;47(4 Suppl 2):S126‐9. ">Klein 1996</a>; <a href="./references#CD011776-bbs2-0060" title="Deloitte Access Economics Report. Economic analysis of motor neurone disease (MND) in Australia. Deloitte Access Economics, commissioned by Motor Neurone Disease Australia, November 2015. http://www.mndaust.asn.au/Influencing‐policy/Economic‐analysis‐of‐MND‐(1)/Economic‐analysis‐of‐MND‐in‐Australia.aspx Accessed 21 December 2016. ">MND Australia 2015</a>)<i>.</i> It is estimated that the per person cost of MND in Australia in 2015 was AUD 1.1 million with a total cost of MND in the country of AUD 2.37 billion, comprising AUD 430.9 million in economic costs and AUD 1.94 billion in burden of disease costs (<a href="./references#CD011776-bbs2-0060" title="Deloitte Access Economics Report. Economic analysis of motor neurone disease (MND) in Australia. Deloitte Access Economics, commissioned by Motor Neurone Disease Australia, November 2015. http://www.mndaust.asn.au/Influencing‐policy/Economic‐analysis‐of‐MND‐(1)/Economic‐analysis‐of‐MND‐in‐Australia.aspx Accessed 21 December 2016. ">MND Australia 2015</a>). A study of Australian people with MND in the community (N = 44) showed that despite most requiring a significant amount of help (more than three times a day) (<a href="./references#CD011776-bbs2-0062" title="NgL , TalmanP , KhanF . Motor neurone disease: disability profile and service needs in an Australian cohort. International Journal of Rehabilitation Research2011;34(2):151‐9. ">Ng 2011</a>), a quarter of these people received assistance solely from family. It is therefore not surprising that primary caregivers have been estimated to spend a mean of 9.5 hours a day caring for a person with MND, even where there is paid assistance (<a href="./references#CD011776-bbs2-0042" title="ChioA , GauthierA , VignolaA , CalvoA , GhiglioneP , CavalloE , et al. Caregiver time use in ALS. Neurology2006;67(5):902‐4. ">Chio 2006</a>). </p> <p>At present, there are few approved drugs for the treatment of MND. Riluzole is the only approved drug treatment for MND in the United States, Australia and in many European countries. It is thought to prolong median survival by about two to three months at one year (<a href="./references#CD011776-bbs2-0020" title="MillerRG , MitchellJD , MooreDH . Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD001447.pub3] ">Miller 2012</a>). Edaravone, an antioxidant free radical scavenger that is believed to relieve the effects of oxidative stress, is licensed in Japan and currently under consideration in the United States (<a href="./references#CD011776-bbs2-0029" title="HenriquesC . FDA accepts pharma's new drug application for ALS therapy edaravone. ALS News Today September 1, 2016 (accessed Oct 2016). [https://alsnewstoday.com/2016/09/01/fda‐accepts‐mitsubishi‐tanabe‐pharma‐nda‐filing‐edaravone‐als] ">ALS 2016</a>). In addition, non‐invasive ventilation is also thought to prolong survival (<a href="./references#CD011776-bbs2-0036" title="BourkeSC , TomlinsonM , WilliamsTL , BullockRE , ShawPJ , GibsonGJ . Effects of non‐invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurology2006;5(2):140‐7. ">Bourke 2006</a>). In the absence of a cure or indeed any medical intervention which might stop the progression of MND, the focus is on symptomatic, rehabilitative, and palliative therapy with an overall aim of optimising quality of life (QoL). </p> <p>There are nine reviews in the Cochrane Library that address the effectiveness of a wide range of symptomatic treatment therapies for people with MND (<a href="./references#CD011776-bbs2-0001" title="AshworthNL , SatkunamLE , DeforgeD . Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004156.pub4] ">Ashworth 2012</a>; <a href="./references#CD011776-bbs2-0002" title="BaldingerR , KatzbergHD , WeberM . Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD004157.pub2] ">Baldinger 2012</a>; <a href="./references#CD011776-bbs2-0003" title="BrettschneiderJ , KurentJ , LudolphA . Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD005226.pub3] ">Brettschneider 2013</a>; <a href="./references#CD011776-bbs2-0004" title="Dal Bello‐HaasV , FlorenceJM . Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD005229.pub3] ">Dal Bello‐Haas 2013</a>; <a href="./references#CD011776-bbs2-0005" title="FangJ , ZhouM , YangM , ZhuC , HeL . Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD008554.pub3] ">Fang 2013</a>; <a href="./references#CD011776-bbs2-0006" title="KatzbergHD , BenatarM . Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD004030.pub3] ">Katzberg 2011</a>; <a href="./references#CD011776-bbs2-0007" title="NgL , KhanF . Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007425.pub2] ">Ng 2009</a>; <a href="./references#CD011776-bbs2-0008" title="RadunovicA , AnnaneD , RafiqMK , MustfaN . Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD004427.pub3] ">Radunovic 2013</a>; <a href="./references#CD011776-bbs2-0009" title="YoungCA , EllisC , JohnsonJ , SathasivamS , PihN . Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006981.pub2] ">Young 2011</a>). This overview draws together the findings from these reviews to make the information more accessible. </p> </section> <section id="CD011776-sec-0018"> <h3 class="title" id="CD011776-sec-0018">Description of the interventions</h3> <p>This review provides an overview of symptomatic treatments for people with MND. Therefore, reviews of therapies that can alter symptoms but which do not target the processes underlying MND are included. Therapies include those that target MND at the impairment level, such as mechanical ventilation for respiratory insufficiency, enteral feeding for maintenance of nutrition impairment, and treatments for spasticity, sialorrhoea, cramps and pain; and those that target MND at the level of activity and participation, such as multidisciplinary care, repetitive transcranial magnetic stimulation (rTMS) and therapeutic exercise. </p> </section> <section id="CD011776-sec-0019"> <h3 class="title" id="CD011776-sec-0019">How the intervention might work</h3> <p>A wide range of interventions is used to treat the diverse symptoms and impairments in MND. At the level of impairment, interventions include the following: </p> <p> <ul id="CD011776-list-0001"> <li> <p>Mechanical ventilation (tracheostomy and non‐invasive ventilation) might prolong survival and optimise QoL by supporting ventilation in those with clinically significant respiratory muscle weakness. </p> </li> <li> <p>Enteral feeding might improve weight maintenance, survival, and QoL by providing a safe and reliable route for nutrition in people with MND who may have a combination of dysphagia, poor appetite, and impaired ability to feed themselves leading to reduced oral intake and malnutrition/dehydration. </p> </li> <li> <p>Spasticity treatments vary widely and may include physiotherapy (for example, therapeutic exercises, stretching, positioning), modalities (for example heat, cold, vibration, electrical stimulation), prescription medication (for example baclofen), non‐prescription medication (for example vitamins), chemical neurolysis (botulinum toxin), surgical interventions (for example intrathecal pumps) and alternative therapies (for example reflexology). How the interventions might work varies widely from one intervention to another. Most commonly, stretching techniques are used in combination with one or more 'true' muscle relaxants (such as baclofen) (<a href="./references#CD011776-bbs2-0041" title="CarterGT , MillerRG . Comprehensive management of amyotrophic lateral sclerosis. Physical Medicine and Rehabilitation Clinics of North America1998;9(1):271‐84, viii‐ix. ">Carter 1998</a>), and such interventions work by lengthening (with or without the assistance of weakening) the agonist muscle. </p> </li> <li> <p>Sialorrhoea treatments include suction, drug treatments and more invasive approaches, such as injection of botulinum toxin or irradiating the salivary glands, which may improve sialorrhoea and QoL. These interventions work by reducing the amount of saliva either through its removal (for example, by suction) or reduction of salivary output (for example, by anticholinergic medications and botulinum toxin injections). </p> </li> <li> <p>Cramps – as the origin of cramps is poorly understood, so too are the mechanisms of treatment. Two different pathophysiological mechanisms have been proposed: abnormal excitation of the terminal branches of motor axons (<a href="./references#CD011776-bbs2-0034" title="BertolasiL , DeGrandisD , BongiovanniLG , ZanetteGP , GasperiniM . The influence of muscular lengthening on cramps. Annals of Neurology1993;33(2):176‐80. ">Bertolasi 1993</a>), and hyperexcitability or bistability of motor neurons at a spinal level (<a href="./references#CD011776-bbs2-0031" title="BaldisseraF , CavallariP , DworzakF . Motor neuron 'bistability'. A pathogenetic mechanism for cramps and myokymia. Brain1994;117(Pt 5):929‐39. ">Baldissera 1994</a>). The aetiology of cramps in MND and the mechanism of action of treatments remains uncertain. </p> </li> <li> <p>Pharmacological pain management works by reducing pain. However, analgesics work on different pathways. For example, paracetamol and non‐steroidal anti‐inflammatory drugs inhibit the production of pain by inhibiting the production of prostaglandins, whilst opiates (such as morphine) imitate natural neuromediators by binding their receptors (such as endorphin receptors). </p> </li> </ul> </p> <p>At the level of activity and participation, interventions include the following:</p> <p> <ul id="CD011776-list-0002"> <li> <p>Multidisciplinary care might reduce disability and improve QoL by applying “a problem‐solving education process” (<a href="./references#CD011776-bbs2-0074" title="WadeDT . Measurement in Neurology Rehabilitation. Oxford: Oxford University Press, 1992. ">Wade 1992</a>), delivered by medical and allied health disciplines (such as physiotherapy, occupational therapy, and speech therapy) that are focused on maximising activity and participation. </p> </li> <li> <p>Transcranial magnetic stimulation might stimulate nerve cells in superficial areas of the brain by applying a high‐energy magnetic field at the skull surface which induces a perpendicular electrical field in the vertical plane through the cortex. It might provide a non‐invasive approach to condition the excitability and activity of neurons (<a href="./references#CD011776-bbs2-0059" title="KobayashiM , Pascual‐LeoneA . Transcranial magnetic stimulation in neurology. Lancet Neurology2003;2(3):145‐56. ">Kobayashi 2003</a>), and at low frequency (equal to or less than 1 Hz), bring a reduction in glutamate‐induced excitotoxicity, which may improve motor function in MND (<a href="./references#CD011776-bbs2-0082" title="ZiemannU , EisenA . TMS for ALS: why and why not. Clinical Neurophysiology2004;115(6):1237‐8. ">Ziemann 2004</a>). At higher frequency (faster than 1 Hz), it is thought that the increased expression of neurotrophic factors could be neuroprotective (<a href="./references#CD011776-bbs2-0030" title="AngelucciF , OlivieroA , PilatoF , SaturnoE , DileoneM , VersaceV , et al. Transcranial magnetic stimulation and BDNF plasma levels in amyotrophic lateral sclerosis. Neuroreport2004;15(4):717‐20. ">Angelucci 2004</a>). </p> </li> <li> <p>Exercise might reduce disability and fatigue and improve QoL by improving cardiovascular deconditioning and disuse weakness. </p> </li> </ul> </p> </section> <section id="CD011776-sec-0020"> <h3 class="title" id="CD011776-sec-0020">Why it is important to do this overview</h3> <p>Nine published Cochrane Systematic Reviews in the Cochrane Library address the effectiveness of a wide range of symptomatic treatment therapies for people with MND specifically. This overview draws together the findings from multiple Cochrane intervention reviews to give clinicians, policy makers and informed consumers a 'friendly front end' for data from a wide range of reviews. This has the benefit of both making the information more accessible and highlighting areas that need further research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011776-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011776-sec-0021"></div> <p>To summarise the evidence from Cochrane Systematic Reviews of all symptomatic treatments for motor neuron disease (MND). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011776-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011776-sec-0022"></div> <section id="CD011776-sec-0023"> <h3 class="title">Criteria for considering reviews for inclusion</h3> <section id="CD011776-sec-0024"> <h4 class="title">Types of reviews</h4> <p>As per Chapter 22 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011776-bbs2-0033" title="BeckerLA , OxmanAD . Chapter 22: Overviews of reviews. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Becker 2011</a>), we considered all Cochrane Systematic Reviews for all treatments for motor neuron disease (MND). These systematic reviews have the following characteristics: </p> <p> <ul id="CD011776-list-0003"> <li> <p>pre‐defined objectives;</p> </li> <li> <p>pre‐defined criteria for eligibility of evidence;</p> </li> <li> <p>an objective systematic search for evidence applying predetermined inclusion and exclusion criteria; and </p> </li> <li> <p>explicit and systematic methods for synthesising evidence, which attempt to reduce bias. </p> </li> </ul> </p> <p>We did not consider non‐Cochrane Systematic Reviews or non‐systematic reviews for inclusion. Where a systematic review included both MND and non‐MND populations we included the systematic review if the review reported results for people with MND separately. </p> </section> <section id="CD011776-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included all forms of MND, regardless of clinical pattern (for example bulbar or limb onset). In participants with amyotrophic lateral sclerosis (ALS), we used the El Escorial and revised El Escorial criteria (<a href="./references#CD011776-bbs2-0038" title='BrooksBR . Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. Journal of the Neurological Sciences1994;124(Suppl):96‐107. '>Brooks 1994</a>; <a href="./references#CD011776-bbs2-0039" title="BrooksBR , MillerRG , SwashM , MunsatTL , World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders2000;1(5):293‐9. ">Brooks 2000</a>). </p> </section> <section id="CD011776-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We included all non‐disease modifying and symptomatic interventions for MND, whether pharmacological or physical. We did not include treatments that target the underlying disease process in MND. These are the subject of a parallel overview of reviews on disease modifying therapies in MND, which is in development. </p> </section> <section id="CD011776-sec-0027"> <h4 class="title">Types of outcomes</h4> <p>In the narrative part of our overview, we report the outcomes reported in the individual Cochrane Systematic Reviews. Where possible, we categorised outcomes according to the International Classification of Functioning, Disability and Health (ICF) (<a href="./references#CD011776-bbs2-0076" title="World Health Organization. International Classification of Functioning, Disability, and Health (ICF). International Classification of Functioning, Disability, and Health (ICF). Geneva: World Health Organization, 2001. ">WHO 2001</a>) into those that focused on: </p> <p> <ul id="CD011776-list-0004"> <li> <p>impairment – for example, forced vital capacity (FVC);</p> </li> <li> <p>disability or limitation in activity – for example, the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS‐R) (the domains of ALSFRS include speech, salivation and swallowing; turning in bed, walking, climbing stairs; dressing and hygiene, handwriting, cutting food; and respiratory insufficiency, dyspnoea, orthopnoea); </p> </li> <li> <p>restriction in participation, and environmental or personal context, or both – for example, mood of the person with MND and their caregiver, satisfaction with services, social integration. </p> </li> </ul> </p> <p>Many of the scales above predate the introduction of the concepts of the ICF domains. The outcome measures often cross boundaries between the concepts of impairment, disability and participation. For example, ALSFRS lists impairments such as dyspnoea and orthopnoea, as well as disabilities such as walking or climbing stairs. Other important outcomes, such as survival and QoL, are not strictly covered by the ICF concepts (although there is again cross‐over of boundaries between ICF concepts and these outcomes). Nevertheless, the ICF provides an important framework, which allows the use of a common standardised language worldwide, hence its application in this overview. Scales used must have been validated as having good reproducibility, face validity and correlation with other scales measuring the same attribute. </p> <p>Outcomes were divided into short‐term (up to 3 months), medium‐term (3 to 12 months) and long‐term (at least 12 months) time points, for both primary and secondary outcomes. </p> <section id="CD011776-sec-0028"> <h5 class="title">Primary outcomes</h5> <p>Primary outcomes focus on domains within QoL and health status after 12 months, such as the Short Form‐36 (SF‐36) or Visual Analogue Scale (VAS) on life satisfaction and well‐being. As QoL is a broad concept, it could be measured by a broad range of scales measuring various aspects of QoL. </p> </section> <section id="CD011776-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p>These include the following short‐term, medium‐term and long‐term outcomes:</p> <p> <ul id="CD011776-list-0005"> <li> <p>outcomes that relate to impairment – for example, forced vital capacity (FVC);</p> </li> <li> <p>outcomes that relate to disability or limitation in activity – for example, Amyotrophic Lateral Sclerosis Severity Scale (ALSSS) and ALSFRS; </p> </li> <li> <p>outcomes that relate to restriction in participation, and environmental or personal context, or both – for example, Caregiver Strain Index (CSI), Utrecht Coping List (UCL); </p> </li> <li> <p>survival;</p> </li> <li> <p>hospitalisation such as readmissions and hospital length of stay (LOS); and</p> </li> <li> <p>cost‐effectiveness of care.</p> </li> </ul> </p> <p>We reported adverse events that may have resulted from the intervention, as defined as events that were fatal, life‐threatening, or required hospitalisation. We also reported side effects from drugs. </p> <p>This review assesses treatments for a range of symptoms. Not all outcomes are relevant to all treatments in an overview of this sort. We have reported outcomes where measured but not commented where outcomes were not relevant to the intervention in question. </p> </section> </section> </section> <section id="CD011776-sec-0030"> <h3 class="title">Search methods for identification of reviews</h3> <p>In November 2016, we searched the <i>Cochrane Database of Systematic Reviews</i> (CDSR) for Cochrane Systematic Reviews of MND. . </p> <p>The search strategy is in <a href="./appendices#CD011776-sec-0088">Appendix 1</a>. </p> </section> <section id="CD011776-sec-0031"> <h3 class="title" id="CD011776-sec-0031">Data collection and analysis</h3> <section id="CD011776-sec-0032"> <h4 class="title">Selection of reviews</h4> <p>Two overview authors (LN and FK) selected systematic reviews for inclusion and resolved disagreements by consensus following discussion with a third overview author (MG). </p> </section> <section id="CD011776-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Two overview authors (LN and FK) independently collected data from published systematic reviews with a data collection form designed to include all the data needed. We used 'Characteristics of included reviews' tables to present the essential features of the included reviews. </p> <p>We resolved disagreements by consensus following discussion with a third author (MG).</p> <p>We contacted the review authors or extracted data from the relevant trials if further information was required. </p> <p>We extracted the following characteristics from the reviews:</p> <p> <ul id="CD011776-list-0006"> <li> <p>date assessed as up to date;</p> </li> <li> <p>objectives;</p> </li> <li> <p>participants;</p> </li> <li> <p>interventions;</p> </li> <li> <p>comparisons;</p> </li> <li> <p>outcomes in the review for which data are available; and</p> </li> <li> <p>limitations.</p> </li> </ul> </p> </section> <section id="CD011776-sec-0034"> <h4 class="title">Assessment of methodological quality of included reviews</h4> <p>Two overview authors, at least one of whom was not an author of the original included reviews, independently assessed the methodological quality of each review included in the overview. For this purpose we used the Assessment of Multiple Systematic Reviews (AMSTAR) tool (<a href="#CD011776-tbl-0001">Table 1</a>) developed by <a href="./references#CD011776-bbs2-0067" title="SheaBJ , GrimshawJM , WellsGA , BoersM , AnderssonN , HamelC , et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology2007;7:10. ">Shea 2007</a>, which has acceptable inter‐rater agreement, construct validity and feasibility (<a href="./references#CD011776-bbs2-0068" title="SheaBJ , HamelC , WellsGA , BouterLM , KristjanssonE , GrimshawJ , et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. Journal of Clinical Epidemiology2009;62(10):1013‐20. ">Shea 2009</a>). Two overview authors (LN and FK) also independently assessed the quality of the evidence in the included reviews with the GRADE approach (<a href="./references#CD011776-bbs2-0052" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>). In both cases, we resolved disagreements by discussion, if necessary with a third author (MG). </p> <div class="table" id="CD011776-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">AMSTAR tool: quality assessment criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Specific requirements</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Was an 'a priori' design provided?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The research question and inclusion criteria should be established before the conduct of the review. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Was there duplicate study selection and data extraction?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. Was a comprehensive literature search performed?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least two electronic sources should be searched. The report must include years and databases used (e.g. CENTRAL, Embase, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialised registers, or experts in the particular field of study, and by reviewing the references in the studies found. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language, etc. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. Was a list of studies (included and excluded) provided?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A list of included and excluded studies should be provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Were the characteristics of the included studies provided?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analysed e.g. age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7. Was the scientific quality of the included studies assessed and documented?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'A priori' methods of assessment should be provided (e.g. for effectiveness studies if the author(s) chose to include only randomised, double‐blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. Was the scientific quality of the included studies used appropriately in formulating conclusions? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The results of the methodological rigour and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9. Were the methods used to combine the findings of studies appropriate?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e. Chi² for homogeneity, I²). If heterogeneity exists a random‐effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e. is it sensible to combine?). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. Was the likelihood of publication bias assessed?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An assessment of publication bias should include a combination of graphical aids (e.g. funnel plot, other available tests) and/or statistical tests (e.g. Egger regression test). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. Was the conflict of interest stated?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>Each criterion judged as 'Yes' (score one point), 'No' (score no point), 'Can't answer' (score no point) or 'Not applicable' (score one point). Total score summed out of a maximum 11 points. </p> </div> </div> </section> <section id="CD011776-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We present data predominantly as a narrative review. We report the evidence for each intervention from each review and its strength in an 'Overview of reviews' table using the GRADE approach. We used the following criteria to assess the quality of the evidence: study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness, and publication bias. We assessed the evidence using GRADE criteria where reviews lack 'Summary of findings' tables. We present data by symptom. </p> <p>In 'Overview of reviews tables' we present:</p> <p> <ul id="CD011776-list-0007"> <li> <p>beneficial and harmful outcomes;</p> </li> <li> <p>frequency or severity of these outcomes in the control groups;</p> </li> <li> <p>estimates of the relative and absolute effects of the interventions;</p> </li> <li> <p>indications of the risk of bias (which may vary by outcome and comparison); and</p> </li> <li> <p>comments.</p> </li> </ul> </p> <p>Where we found more than one eligible review of a particular intervention and the conclusions agreed, we report this; where the conclusions differed, we further explored this, taking into account the AMSTAR scores of the included reviews. </p> <p>Due to the heterogeneity of the included systematic reviews, it was not possible to perform statistically valid direct or indirect comparisons on the interventions contained within this overview. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011776-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011776-sec-0036"></div> <section id="CD011776-sec-0037"> <h3 class="title" id="CD011776-sec-0037">Description of included reviews</h3> <p>We identified 82 Cochrane Systematic Reviews in the <i>Cochrane Database of Systematic Reviews</i> (CDSR). Of these, 30 passed the first screening review and were selected for closer scrutiny. We excluded 18 reviews (<a href="#CD011776-tbl-0002">Table 2</a>); three others were reviews in palliative care conditions but did not have content relating specifically to motor neuron disease (MND); hence we included nine reviews (<a href="#CD011776-tbl-0003">Table 3</a>). </p> <div class="table" id="CD011776-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of excluded reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reason for exclusion</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0010" title="Abdul WahidSF , LawZK , LaiNM , IsmailNA , Azman AliR . Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011742] ">Abdul Wahid 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> <p>Disease‐modifying treatments (since published in CENTRAL, Issue 10, 2016 in the Cochrane Library) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0019" title="MaguireC , McDermottC , HindD , RadunovicA , ShawPJ . Diaphragm pacing systems for amyotrophic lateral sclerosis / motor neuron disease. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD011222] ">Maguire 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0027" title="YoungCA , GibbonsC , PagniniF , FriedeT . Treatment for fatigue in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD011005] ">Young 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0023" title="PastulaDM , MooreDH , BedlackRS . Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD005225.pub3] ">Pastula 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0012" title="BeauverdM , MitchellJD , WokkeJHJ , BorasioGD . Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD002064.pub3] ">Beauverd 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0026" title="YiZM , LiuF , ZhaiSD , BelshJ , ZhanSY , SchiffmanP . Pharmacological interventions for improving respiratory function in amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD010030] ">Yi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0020" title="MillerRG , MitchellJD , MooreDH . Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD001447.pub3] ">Miller 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0013" title="BenatarM , KurentJ , MooreDH . Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006153.pub2] ">Benatar 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0015" title="BongioanniP , BorasioGD , OliverD , TramontiF , RomagnoliA , KapitzaKP . Methods for informing people with amyotrophic lateral sclerosis/motor neuron disease of their diagnosis. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD007593] ">Bongioanni 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> <p>Not related to treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0025" title="SathasivamS , Addison‐JonesR , MillerRG , MooreDH , YoungCA . Minocycline for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD006840] ">Sathasivam 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0021" title="OrrellRW , LaneRJM , RossM . Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002829.pub4] ">Orrell 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0016" title="DianaA , SogosV , BongioanniP , MillerRG , MooreDH . Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD006049] ">Diana 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0014" title="BongioanniP , RealiC , SogosV . Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004302.pub2] ">Bongioanni 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0011" title="AnnaneD , OrlikowskiD , ChevretS . Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD001941.pub3] ">Annane 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results for people with MND are not reported separately</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0024" title="PayneC , WiffenPJ , MartinS . Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD008427.pub2] ">Payne 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies included in this review for people with MND are already covered in the included studies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0018" title="LeeCN . Reviewing evidences on the management of patients with motor neuron disease. Hong Kong Medical Journal2012;18:48‐55. ">Lee 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not a systematic review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0017" title="GoodP , RichardR , SyrmisW , Jenkins‐MarshS , StephensJ . Medically assisted nutrition for adult palliative care patients. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD006274.pub3] ">Good 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies included in this review for people with MND are already covered in the included studies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0022" title="PaoloB , NicolaT , AgataL , AndreaG , AntonelloN , VincenzoS . A review of options for treating sialorrhea in amyotrophic lateral sclerosis. Respiratory Care2015;60(3):446‐54. ">Paolo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not a systematic review</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011776-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author/year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Date assessed as up to date</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary and secondary outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Limitations*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0003" title="BrettschneiderJ , KurentJ , LudolphA . Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD005226.pub3] ">Brettschneider 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any drug therapy, given by any route, in any dose, administered to relieve pain in ALS/MND </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated but assumed one intervention to another or to placebo or no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (impairment):</p> <p> <ul id="CD011776-list-0008"> <li> <p>Pain relief (after 24 hours) (VAS or any other validated scales)</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0009"> <li> <p>Pain relief (after 7 days)</p> </li> </ul> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0002" title="BaldingerR , KatzbergHD , WeberM . Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD004157.pub2] ">Baldinger 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feb 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any drug therapy (oral, subcutaneous or intravenous) or physical treatment which potentially relieves cramps in ALS/MND </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated but assumed one intervention to another or to placebo or no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>impairment</i>): </p> <p> <ul id="CD011776-list-0010"> <li> <p>Reduction in subjective global impression of muscle cramp burden measured through VAS </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0011"> <li> <p>Cramp intensity/number of cramps in 24 hours preceding assessment by VAS</p> </li> <li> <p>Ratio of participants experiencing cramps to total number of participants (in studies where cramps were assessed as adverse events) </p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0012"> <li> <p>QoL</p> </li> </ul> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0001" title="AshworthNL , SatkunamLE , DeforgeD . Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004156.pub4] ">Ashworth 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Physical therapy/physiotherapy</p> <p>2) Modalities (e.g. heat, cold, vibration, electrical stimulation)</p> <p>3) Non‐prescription medications (e.g. vitamins, herbals, diet supplements)</p> <p>4) Chemical neurolysis (e.g. phenol blocks, botulinum toxin)</p> <p>5) Surgical intervention (e.g. intrathecal pumps, tenotomy, dorsal rhizotomy)</p> <p>6) Alternative therapies (e.g. reflexology, aromatherapy, relaxation techniques)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated but assumed one intervention to another or to placebo or no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>impairment</i>): </p> <p> <ul id="CD011776-list-0013"> <li> <p>Reduction in spasticity at three months as measured by Ashworth (or modified Ashworth) spasticity scale </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0014"> <li> <p>Reduction in spasticity based on history (e.g. spasm frequency score), physical examination (e.g. reflex score) or physiology (e.g. pendulum test) </p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0015"> <li> <p>Disability/activity limitation (e.g. functional independence measure)</p> </li> <li> <p>QoL</p> </li> </ul> </p> <p><i>Adverse events</i> </p> <p><i>Cost‐effectiveness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0008" title="RadunovicA , AnnaneD , RafiqMK , MustfaN . Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD004427.pub3] ">Radunovic 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>May 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All forms of non‐invasive ventilation (NIV) and tracheostomy assisted ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No intervention or best standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p> <ul id="CD011776-list-0016"> <li> <p>Survival as assessed by pooled hazards ratio using life table/Cox regression methods to combine disparate periods of observation from all studies </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD011776-list-0017"> <li> <p>Survival at 1 month and 6 months and longer</p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0018"> <li> <p>Function – such as ALSFRS</p> </li> <li> <p>QoL</p> </li> </ul> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0009" title="YoungCA , EllisC , JohnsonJ , SathasivamS , PihN . Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006981.pub2] ">Young 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>September 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Any drug treatment administered via any route</p> <p>2) Injection of botulinum toxin in parotid and/or submandibular glands</p> <p>3) Radiotherapy to the salivary glands</p> <p>4) Surgical techniques, for example the ligation of parotid and submandibular salivary ducts </p> <p>5) Other treatments identified in the literature such as complementary therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One intervention to another or to placebo or no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>impairment</i>): </p> <p> <ul id="CD011776-list-0019"> <li> <p>Subjective improvement in sialorrhoea</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ol id="CD011776-list-0020"> <li> <p>Reduction in amount of saliva production using an objective measure such as weight of swabs or amount of tissue used </p> </li> </ol> </p> <p><i>Activity and participation</i> </p> <p> <ol id="CD011776-list-0021"> <li> <p>QoL</p> </li> </ol> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0006" title="KatzbergHD , BenatarM . Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD004030.pub3] ">Katzberg 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>September 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placement of percutaneous endoscopic gastrostomy (PEG) or other tube feeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No feeding tube and continued oral intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p> <ul id="CD011776-list-0022"> <li> <p>Survival time</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ol id="CD011776-list-0023"> <li> <p>Quantitative index of change in nutritional status (e.g. weight change, change in body mass index, other nutritional markers such as pre‐albumin level) </p> </li> </ol> </p> <p><i>Activity and participation</i> </p> <p> <ol id="CD011776-list-0024"> <li> <p>QoL</p> </li> </ol> </p> <p><i>Adverse events (safety of PEG)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0005" title="FangJ , ZhouM , YangM , ZhuC , HeL . Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD008554.pub3] ">Fang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Repetitive transcranial magnetic stimulation (rTMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No intervention or sham rTMS or physiotherapy or medications or different methods of applications of rTMS such as high‐frequency (&gt; 1 Hz) compared to low frequency (≤ 1 Hz) rTMS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>activity and participation</i>): </p> <p> <ul id="CD011776-list-0025"> <li> <p>Disability or limitation in activity as measured by ALSFRS‐R (6 months)</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0026"> <li> <p>Changes to muscle strength as measured by Manual Muscle Testing (1 and 6 months or longer) </p> </li> <li> <p>Changes to fatigue as measured by Fatigue Severity Scale (1 and 6 months or longer)</p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0027"> <li> <p>Disability or limitation in activity as measured by ALSFRS‐R (12 months)</p> </li> </ul> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0004" title="Dal Bello‐HaasV , FlorenceJM . Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD005229.pub3] ">Dal Bello‐Haas 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressive resistance or strengthening exercise and endurance or aerobic exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No exercise or standard rehabilitation management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>activity and participation</i>): </p> <p> <ul id="CD011776-list-0028"> <li> <p>Improvement in functional ability, decrease in disability or reduction in rate of decline as measured by ALSFRS‐R or other validated outcome measures (3 months) </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0029"> <li> <p>Decrease in fatigue</p> </li> <li> <p>Change in rate of decline of muscle strength</p> </li> <li> <p>Change in rate of decline of aerobic endurance</p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0030"> <li> <p>Improvement in psychological status or QoL</p> </li> </ul> </p> <p><i>Adverse events</i> </p> <p>(all at 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0062" title="NgL , TalmanP , KhanF . Motor neurone disease: disability profile and service needs in an Australian cohort. International Journal of Rehabilitation Research2011;34(2):151‐9. ">Ng 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multidisciplinary care as defined by any intervention delivered by two or more allied health disciplines (includes nursing physiotherapy, occupational therapy, speech therapy, etc.), directed by a physician, designed to be patient‐centred and aimed at maximising activity and participation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lower level or different type of intervention such as “routinely available local services” or “minimal intervention” (such as information only), waiting list conditions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcomes (<i>activity and participation</i>): </p> <p> <ul id="CD011776-list-0031"> <li> <p>Improvement in QoL</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0032"> <li> <p>Improvement in Impairment (e.g. FVC)</p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0033"> <li> <p>Improvement in functional ability (e.g. ALSFRS)</p> </li> <li> <p>Participation and environmental or personal context (e.g. caregiver strain index)</p> </li> </ul> </p> <p><i>Survival</i> </p> <p><i>Hospitalisation such as readmission and hospital length of stay</i> </p> <p><i>Adverse events</i> </p> <p><i>Cost‐effectiveness of care</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Not clearly covered by AMSTAR assessment</p> <p>Abbreviations: ALSFRS: Amyotrophic Lateral Sclerosis Functional Rating Scale; FVC: forced vital capacity; QoL: quality of life; RCT: randomised controlled trial; VAS: visual analogue scale </p> </div> </div> <p>The nine included reviews address the effectiveness of a range of symptomatic treatment therapies for people with MND at both the level of impairment and at the level of activity and participation. At the level of impairment, interventions included: drug therapy for pain (<a href="./references#CD011776-bbs2-0003" title="BrettschneiderJ , KurentJ , LudolphA . Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD005226.pub3] ">Brettschneider 2013</a>), treatment for cramps (<a href="./references#CD011776-bbs2-0002" title="BaldingerR , KatzbergHD , WeberM . Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD004157.pub2] ">Baldinger 2012</a>), treatment for spasticity (<a href="./references#CD011776-bbs2-0001" title="AshworthNL , SatkunamLE , DeforgeD . Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004156.pub4] ">Ashworth 2012</a>), mechanical ventilation for supporting respiratory function (<a href="./references#CD011776-bbs2-0008" title="RadunovicA , AnnaneD , RafiqMK , MustfaN . Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD004427.pub3] ">Radunovic 2013</a>), treatment for sialorrhoea (<a href="./references#CD011776-bbs2-0009" title="YoungCA , EllisC , JohnsonJ , SathasivamS , PihN . Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006981.pub2] ">Young 2011</a>), and enteral tube supporting nutrition (<a href="./references#CD011776-bbs2-0006" title="KatzbergHD , BenatarM . Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD004030.pub3] ">Katzberg 2011</a>). At the level of activity and participation, interventions included rTMS (<a href="./references#CD011776-bbs2-0005" title="FangJ , ZhouM , YangM , ZhuC , HeL . Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD008554.pub3] ">Fang 2013</a>), therapeutic exercise (<a href="./references#CD011776-bbs2-0004" title="Dal Bello‐HaasV , FlorenceJM . Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD005229.pub3] ">Dal Bello‐Haas 2013</a>), and multidisciplinary care (<a href="./references#CD011776-bbs2-0007" title="NgL , KhanF . Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007425.pub2] ">Ng 2009</a>). </p> </section> <section id="CD011776-sec-0038"> <h3 class="title" id="CD011776-sec-0038">Methodological quality of included reviews</h3> <p>See <a href="#CD011776-tbl-0004">Table 4</a> for methodological quality of the reviews and <a href="#CD011776-tbl-0005">Table 5</a> for methodological quality of studies within included systematic reviews. </p> <div class="table" id="CD011776-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AMSTAR ratings of included reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author/year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Brettschneider 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baldinger 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ashworth 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radunovic 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Young 2011</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Katzberg 2011</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fang 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dal Bello‐Haas 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ng 2011</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'A priori' design for the systematic review provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duplicate study selection and data extraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comprehensive literature search</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Search for studies regardless of their publication type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>List of included and excluded studies provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Characteristics of included studies provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scientific quality of included studies assessed and documented</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scientific quality of included studies used appropriately in formulating conclusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriate methods used to combine study findings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Likelihood of publication bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conflict of interest stated for both the systematic review and included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total score (n/11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Y = Yes – criteria met (score one point), N= No – criteria not met (score 0 points), CA = Can't answer (score 0 points), NA= not applicable (score 1 point) </p> </div> </div> <div class="table" id="CD011776-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Overview of reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Interventions at the level of impairment/symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Drug therapy for pain</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author/year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes in the review for which data are available</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of the evidence (GRADE) for reported efficacy outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0003" title="BrettschneiderJ , KurentJ , LudolphA . Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD005226.pub3] ">Brettschneider 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Treatment for cramps</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0002" title="BaldingerR , KatzbergHD , WeberM . Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD004157.pub2] ">Baldinger 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 RCTs</p> <p>N = 4012<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tetrahydrocannabinol (THC), vitamin E, baclofen, riluzole, L‐threonine, xaliproden, memantine, gabapentin, </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p> <ul id="CD011776-list-0034"> <li> <p>Memantine, tetrahydrocannabinol (THC) are probably ineffective (moderate‐quality evidence)</p> </li> <li> <p>vitamin E may be ineffective</p> </li> <li> <p>It is uncertain whether L‐threonine, gabapentin, xaliproden, riluzole, or baclofen are effective (very low quality evidence, or data not reported) </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ol id="CD011776-list-0035"> <li> <p>Cramp intensity/number of cramps in 24 hours preceding assessment by VAS – no statistical difference for THC (not assessed in other studies) </p> </li> <li> <p>Ratio of participants experiencing cramps to total number of participants (in studies where cramps were assessed as adverse events) – not an outcome of interest in this review </p> </li> <li> <p>QoL – not measured</p> </li> <li> <p>Adverse events</p> </li> </ol> </p> <p>Adverse effects for riluzole 100 mg/day – increased asthenia, spasticity, increase in liver enzymes, impaired respiratory function, and elevation in blood pressure </p> <p>Adverse effects for vitamin E, baclofen, gabapentin, L‐threonine, xaliproden, memantine and THC not stated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low:</p> <p>L‐threonine – 3 studies with very high risk of bias (very small sample sizes, unclear randomisation process and allocation concealment, incomplete outcome data) </p> <p>Baclofen – 1 study with high risk of bias and very small sample sizes; subjective impression of cramps listed as an outcome but data not reported </p> <p>Low:</p> <p>Vitamin E – 1 study with clear randomisation, allocation concealment, and blinding, but high risk of selective reporting given change in protocol and no information given on number of participants at 12 months or date of last examination </p> <p>Moderate:</p> <p>THC – 1 study with low risk of bias</p> <p>Memantine – 1 study with low risk of bias</p> <p>Outcome not reported:</p> <p>Riluzole – 3 studies, 2 of which had high risk of bias due to incomplete reporting and 1 at low risk of bias; cramps listed as an outcome but data not reported </p> <p>Xaliproden – 2 studies with low risk of bias; cramps an outcome but results not given</p> <p>Gabapentin – 1 study with low risk of bias. Cramps an outcome but data not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Treatment for spasticity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0001" title="AshworthNL , SatkunamLE , DeforgeD . Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004156.pub4] ">Ashworth 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT N = 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endurance exercises</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Usual activities”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p>Reduction in spasticity in favour of treatment group (mean reduction of −0.43, 95% CI −1.03 to 0.17 in intervention vs increase of 0.25, 95% CI −0.46 to 0.96 in control) </p> <p>Secondary outcomes:</p> <p>No statistically significant differences between exercise and placebo groups in muscle strength (manual muscle testing, fatigue (fatigue severity scale) and QoL (SF‐36). No adverse effects reported. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low:<br/> 1 trial with high risk of bias, unclear randomisation, no allocation concealment, no blinding, 50% attrition by 6 months. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Mechanical ventilation for supporting respiratory function</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0008" title="RadunovicA , AnnaneD , RafiqMK , MustfaN . Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD004427.pub3] ">Radunovic 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT N = 41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐invasive ventilation (NIV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Standard care"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p>Median survival was 48 days longer (219 days vs 171 days) compared to the standard care group (estimated 95% CI 12 to 91 days, P = 0.0062). In subgroup analyses, median survival of subgroup with good or moderately impaired bulbar function was significantly different in favour of NIV group (P = 0.0059) with survival 205 days longer than standard care participants (median 216 in NIV group vs 11 days in standard care group). In participants with poor bulbar function, NIV did not confer survival advantage (P = 0.92). </p> <p>Secondary outcomes:</p> <p>1) QoL – significant benefit in favour of NIV in <i>maintenance</i> of QoL in good or moderately impaired bulbar function subgroup (P = 0.0017 SF‐35 Health Survey mental component summary score; P = 0.0013 mean symptoms domain of the sleep apnoea QoL index) and significant benefit in favour of NIV in subgroup of poor bulbar function in <i>improvement</i> in mean symptoms domain of the sleep apnoea QoL index but not in the SF‐36 Health Survey mental component summary score </p> <p>2) Function – such as ALSFRS – not measured</p> <p>3) No adverse events reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate:<br/> 1 trial with low risk of bias (clear random sequence generation, adequate allocation concealment, data was complete and there was no selective reporting or other bias. Blinding of participants was not possible and it was unclear if outcome assessors were blinded). </p> <p>Originally 2 RCTs were identified with a total of 54 participants; however, 1 was a pilot study with no study protocol and incomplete data (data available for 6 out of the 13 participants) and was therefore not included in meta‐analysis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Treatment for sialorrhoea</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0009" title="YoungCA , EllisC , JohnsonJ , SathasivamS , PihN . Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006981.pub2] ">Young 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Botulinum toxin B injection into parotid and submandibular glands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (normal saline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:<br/> Subjective improvement in sialorrhoea at week 2 and 4 in favour of treatment group (treatment 82% improved, placebo 38%, P &lt; 0.05 at week 2; treatment 90% improved, placebo 44%, P &lt; 0.05 at week 4. No statistically significant difference at week 8 or 12. </p> <p>Secondary outcomes:</p> <p>1) Volume of saliva produced as measured with funnel and tube over 5 min – significant difference in favour of treatment group at week 2 (treatment 0.07, SD 0.2; placebo 0.84, SD 0.8, P &lt; 0.05) and week 4 (treatment 0.02, SD 0.04; placebo 0.97, SD 0.5, P &lt; 0.05), but not at week 8 or 12. </p> <p>2) QoL as measured by clinicians' assessment of marked improvement using the SEIQOL‐DW showed a statistically significant difference from baseline with botulinum toxin but not placebo at week 2 but not at later time points </p> <p>3) No adverse events reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate:<br/> 1 trial, small sample size but low risk of bias. By 12 weeks, 70% of investigators and 90% of participants guessed treatment allocation correctly suggesting that despite excellent attempts to maintain blinding, the double‐blind was not preserved. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Enteral tube feeding for supporting nutrition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0006" title="KatzbergHD , BenatarM . Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD004030.pub3] ">Katzberg 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Interventions at the level of activity and participation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Repetitive transcranial magnetic stimulation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0005" title="FangJ , ZhouM , YangM , ZhuC , HeL . Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD008554.pub3] ">Fang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 RCTs, N = 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Repetitive transcranial magnetic stimulation (rTMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham rTMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcomes: not measured.</p> <p>Secondary outcomes:</p> <p>No statistical difference in disability or limitation in activity as measured by ALSFRS‐R (12 months) or muscle strength. </p> <p>Changes to fatigue not measured.</p> <p>No adverse effects reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low:<br/> All trials of poor methodological quality (2 of the 3 were missing raw numerical data), insufficiently homogenous to pool results, small sample sizes and high attrition (30% to 40%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Therapeutic exercise</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0004" title="Dal Bello‐HaasV , FlorenceJM . Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD005229.pub3] ">Dal Bello‐Haas 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs, N = 43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exercise (endurance or resistance)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Usual activities” or “usual care” (stretching exercise)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:<br/> Significant improvement in disability or limitation in activity as measured by ALSFRS in favour of exercise groups (3 months) (MD 3.21, 95% CI 0.46 to 5.96) </p> <p>Secondary outcomes:<br/> No statistically significant differences between exercise and placebo groups in QoL (SF‐36), fatigue (fatigue severity scale) or muscle strength (manual muscle testing). </p> <p>No adverse effects reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low:<br/> Both trials had small sample sizes. 1 trial had a low risk of bias, whilst the other had high attrition (close to 30% by 3 months), no allocation concealment, and no blinding. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Multidisciplinary care</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0062" title="NgL , TalmanP , KhanF . Motor neurone disease: disability profile and service needs in an Australian cohort. International Journal of Rehabilitation Research2011;34(2):151‐9. ">Ng 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ALSFRS: Amyotrophic Lateral Sclerosis Functional Rating Scale; ALSFRS‐R: Amyotrophic Lateral Sclerosis Functional Rating Scale Revised; CI: confidence interval; MD: mean difference; QoL: quality of life; RCT: randomised controlled trial; SD: standard deviation; SEIQOL‐DW: Schedule for Evaluation of Individual Quality of Life‐Direct Weighting; SF: Short Form Health Survey; vs: versus. </p> <p>1. The review includes 20 trials, of which 7 assess cramps as an adverse event. We did not report the trials of cramps assessed as an adverse event in this overview. </p> </div> </div> <p>All the included reviews achieved an Assessment of Multiple Systematic Reviews (AMSTAR) rating of either 10 or 11 out of 11 (<a href="./references#CD011776-bbs2-0067" title="SheaBJ , GrimshawJM , WellsGA , BoersM , AnderssonN , HamelC , et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology2007;7:10. ">Shea 2007</a>), and we deemed them of high methodological quality. There were three 'empty' reviews (<a href="./references#CD011776-bbs2-0003" title="BrettschneiderJ , KurentJ , LudolphA . Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD005226.pub3] ">Brettschneider 2013</a>; <a href="./references#CD011776-bbs2-0006" title="KatzbergHD , BenatarM . Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD004030.pub3] ">Katzberg 2011</a>; <a href="./references#CD011776-bbs2-0007" title="NgL , KhanF . Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007425.pub2] ">Ng 2009</a>), defined as reviews with no included studies. For these reviews, a number of criteria were not applicable (characteristics of included studies provided; scientific quality of included studies assessed and documented; scientific quality of included studies used appropriately in formulating conclusions; appropriate methods used to combine study findings; likelihood of publication bias; conflict of interest stated for both the systematic review and included studies). None of the reviews that contained included studies scored a point for “Conflict of interest stated for both the systematic review and included studies”. Whilst all the reviews clearly stated conflicts of interest for the review, none reported conflict of interest for included studies within the review. </p> <p>For all reviews with included studies, at least two review authors independently assessed the risk of bias in each study using the same tools. The review authors considered risk of bias for seven methodological domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome reporting, selective outcome reporting and other sources of bias. We assessed these domains according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. We judged each of the criteria relating to the risk of bias as 'low risk', 'high risk' or 'unclear risk' and we resolved any disagreements through discussion with a third author. </p> <p>In <a href="#CD011776-tbl-0005">Table 5</a> 'Overview of reviews', we reported the evidence for each intervention from each review and its strength using the GRADE approach, using the criteria of study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness, and publication bias. In the reviews where the review authors had used GRADE to determine the strength of the evidence for each intervention, we reassessed the grading of evidence where we felt that a different grade would more accurately reflect the level of evidence. For example, in the review for treatment for cramps, the review authors judged studies with very small sample sizes (underpowered to detect an effect) but otherwise at low risk of bias to be of moderate quality. We downgraded them to low quality in this overview. Where the strength of evidence was based on a single study alone with a low risk of bias, we decided that the quality of evidence could at best be moderate and not high. </p> </section> <section id="CD011776-sec-0039"> <h3 class="title" id="CD011776-sec-0039">Effect of interventions</h3> <section id="CD011776-sec-0040"> <h4 class="title">Interventions at the level of impairment</h4> <section id="CD011776-sec-0041"> <h5 class="title">Drug therapy for pain</h5> <p>In the Cochrane Systematic Review by <a href="./references#CD011776-bbs2-0003" title="BrettschneiderJ , KurentJ , LudolphA . Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD005226.pub3] ">Brettschneider 2013</a>, the review authors found no randomised controlled trials (RCTs) or quasi‐RCTs on drug therapy for pain experienced as part of motor neuron disease (MND). This was unsurprising given the ethical concerns around designing a placebo‐controlled trial for treatment of pain in MND. The review authors therefore considered non‐randomised evidence in the form of retrospective case series of more than five participants where people were treated consecutively, and found 13 case studies suggesting that pain occurs in up to 78% of people with MND and that frequency and intensity of pain increases with ongoing disease. Pain was most frequently associated with reduced joint mobility, cramps, or skin pressure caused by immobility. Paracetamol or other non‐steroidal anti‐inflammatory drugs (NSAIDs) were commonly used as first line treatment. However, in the later stages of disease, opioids were reported as more effective for pain and also had a concurrent beneficial effect on dyspnoea and insomnia. The authors concluded that pain was a common unresolved problem in MND. In the absence of any evidence from RCTs, and utilising non‐randomised evidence, they concluded that treatment for pain in MND should follow the 1990 World Health Organization (WHO) Analgesic Ladder (<a href="./references#CD011776-bbs2-0075" title="Cancer pain relief and palliative care. Report of a WHO Expert Committee1990; Vol. World Health Organization Technical Report Series, issue 804:1‐75. ">WHO 1990</a>). </p> </section> <section id="CD011776-sec-0042"> <h5 class="title">Treatment for cramps</h5> <p><a href="./references#CD011776-bbs2-0002" title="BaldingerR , KatzbergHD , WeberM . Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD004157.pub2] ">Baldinger 2012</a> identified 13 RCTs (N = 4012), in which interventions for cramps were studied in participants with MND, of which one study (tetrahydrocannabinol) assessed cramps as the primary endpoint. Twelve studies (of vitamin E, baclofen, riluzole, L‐threonine, xaliproden, gabapentin, or memantine) assessed cramps as a secondary endpoint. The systematic review also included six studies (of creatine, gabapentin, indinavir, dextromethorphan, quinidine, or lithium) that assessed cramps as an adverse event, but we did not consider them in this treatment overview. Assessment time points varied widely. The review did not report adverse events from interventions for cramps other than for riluzole; it is unclear whether other trials did not report adverse events or whether no adverse events occurred (see <a href="#CD011776-tbl-0005">Table 5</a>). Most trials assessed cramps at regular intervals (ranging from weekly to 12‐weekly) and one of the studies had a single assessment time point at 12 months. In none of the studies was there a clear benefit from any of the medications. However, many studies were underpowered to draw a definite conclusion. Notably, the review authors identified no studies using physical therapy as a therapeutic intervention for cramps. </p> </section> <section id="CD011776-sec-0043"> <h5 class="title">Treatment for spasticity</h5> <p><a href="./references#CD011776-bbs2-0001" title="AshworthNL , SatkunamLE , DeforgeD . Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004156.pub4] ">Ashworth 2012</a> found a single RCT addressing the treatment of spasticity in MND, in which spasticity (as measured by the Ashworth Scale) was improved at 3 months following an endurance‐based exercise programme. The study had a very small sample size (N = 25) and was at high risk of bias. Significantly, attrition was high enough to be a “fatal flaw”: 30% of participants had been lost at 3 months, 50% at 6 months, and so many at 9 or 12 months that no further analyses could be done. There was no statistically significant improvement in QoL and no adverse events were reported. The review authors concluded that based on this single study, it was not possible to determine whether individualised moderate‐intensity endurance‐type exercise was beneficial or harmful and that current practice, which includes anti‐spasticity drugs such as baclofen and a programme of regular stretching, required more research, especially considering the potential harm from these drugs through worsening muscle weakness and function. </p> </section> <section id="CD011776-sec-0044"> <h5 class="title">Mechanical ventilation for supporting respiratory function</h5> <p><a href="./references#CD011776-bbs2-0008" title="RadunovicA , AnnaneD , RafiqMK , MustfaN . Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD004427.pub3] ">Radunovic 2013</a> identified two RCTs involving 54 participants with MND receiving non‐invasive ventilation (NIV). The review authors were unable to analyse one of the studies as it had incomplete data (6 out of 13 participants). It also had no clear protocol as it was originally designed as a pilot study and did not receive funding for continuation. Results of the Cochrane Systematic Review were therefore based on a single well‐conducted RCT of non‐invasive ventilation versus standard care, which was at low risk of bias (N = 41). Outcomes included survival and QoL (measured until at least 12 months or until death). Overall median survival was significantly improved in the NIV group (219 days compared to 171 days for standard care) and the survival benefit was predominantly in the subgroup with normal to moderately impaired bulbar function. NIV also resulted in a benefit in the maintenance of QoL for most of the duration of survival in this subgroup. Whilst NIV did not prolong survival in participants with poor bulbar function, there was a significant improvement in the 'Mean Symptoms' domain of the Sleep Apnoea Quality of Life Index, but not in the Short Form‐36 Health Survey Mental Component Summary score. Function was not measured and no adverse events were reported. The authors of the review reported that, given the RCT confirmed previous observational studies, which have shown survival advantage and improved QoL in people with MND who start and can tolerate NIV at the onset of respiratory impairment, ethically it was unlikely that there would be further randomised controlled trials of NIV in unselected cohorts of people with MND. The review did not assess when to start NIV. Additionally, the National Institute for Health and Clinical Excellence has carried out a cost‐effectiveness analysis using the Markov Model and concluded that the use of NIV in the management of people with MND represents a cost‐effective use of resources (<a href="./references#CD011776-bbs2-0063" title="National Institute for Health and Care Excellence. Motor neuron disease: the use of non‐invasive ventilation in the management of motor neurone disease. NICE Clinical Guidelines, No. 105. Centre for Clinical Practice at NICE (UK). London: National Institute for Health and Clinical Excellence (UK)2010. ">NICE 2010b</a>). </p> </section> <section id="CD011776-sec-0045"> <h5 class="title">Treatment for sialorrhoea</h5> <p><a href="./references#CD011776-bbs2-0009" title="YoungCA , EllisC , JohnsonJ , SathasivamS , PihN . Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006981.pub2] ">Young 2011</a> identified a single RCT relating to treatment of sialorrhoea in MND which involved botulinum toxin type B injections. The results favoured a single session of botulinum toxin type B injections to parotid and submandibular glands, which produced both subjective and objective benefits in people with MND for up to 4 weeks. However, effects appeared to be lost by 8 to 12 weeks. Other than the relatively small sample size (N = 20), the study was methodologically robust (randomisation and analysis appeared good and data completeness was satisfactory) and findings were supported by other non‐randomised trials (which were included in the discussion); these were typically open label studies on the use of botulinum toxin to reduce saliva production in MND. Although no adverse events were reported in this RCT, serious adverse events such as infection of the salivary gland and dysphagia have previously been reported with this intervention (<a href="./references#CD011776-bbs2-0079" title="WinterhollerMG , ErbguthJF , WolfS , KatS . Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. Journal of Neurology, Neurosurgery &amp; Psychiatry2001;70(3):417‐8. ">Winterholler 2001</a>). </p> </section> <section id="CD011776-sec-0046"> <h5 class="title">Enteral tube feeding for supporting nutrition</h5> <p><a href="./references#CD011776-bbs2-0006" title="KatzbergHD , BenatarM . Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD004030.pub3] ">Katzberg 2011</a> did not identify any RCTs that evaluated the efficacy of percutaneous endoscopic gastrostomy (PEG) or other feeding tube placement. There were, however, 11 non‐RCTs relating to PEG insertion that the review authors identified and discussed. All 11 studies tested for a possible survival advantage. Two prospective and two retrospective studies reported a longer survival in people with MND (regardless of limb or bulbar onset) after PEG compared to people feeding orally, whilst one prospective and six retrospective studies failed to find a survival advantage. The trial authors noted, however, that the latter studies had multiple design flaws, the major flaw being lack of control for confounders. Katzberg and colleagues concluded that survival advantage was weakly positive. Nutrition was not as rigorously studied, but the three studies that did assess nutrition found a positive outcome for PEG. The studies did not assess QoL effectively and the review authors drew no conclusions about this outcome. In terms of safety, the frequency of minor complications of PEG tube insertion ranged from 2% to 16% and major complications, mostly comprising PEG failure, occurred in up to 45% of participants. Complications during the procedure itself (including death) were infrequently reported. There was little evidence to guide timing of PEG insertion, with some evidence that PEG insertion may be more risky in people with a forced vital capacity (FVC) less than 50%, but there is also evidence that even people with MND with low FVC may still benefit from PEG placement, particularly when NIV is used during the procedure. Four studies compared the effectiveness and safety of percutaneous radiological gastrostomy (PRG), which is also known as radiologically inserted gastrostomy (RIG), to PEG and found them equally effective with similar rates of complications. </p> </section> </section> <section id="CD011776-sec-0047"> <h4 class="title">Interventions at the level of activity and participation</h4> <section id="CD011776-sec-0048"> <h5 class="title">Repetitive transcranial magnetic stimulation (rTMS)</h5> <p><a href="./references#CD011776-bbs2-0005" title="FangJ , ZhouM , YangM , ZhuC , HeL . Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD008554.pub3] ">Fang 2013</a> aimed to determine the efficacy of rTMS primarily on disability or limitation in activity. Three studies with small sample sizes (50 participants in total) compared rTMS with sham TMS. There was heterogeneity in the rTMS technique with respect to duration of treatment, frequency of rTMS and intensity of rTMS. Outcome measurement time points also varied widely between the three studies (4 weeks, 6 months, and 12 months). None of the three studies provided detailed data on the ALS Functional Rating Scale‐Revised (ALSFRS‐R) at six months which was the pre‐assigned primary outcome in the review. The trials provided only statistical summary data, with no raw numerical data. Of the two studies that provided statistical summary data on ALSFRS‐R at 6 months, the results were conflicting, with one indicating a benefit and the other finding no statistical difference. Little or no difference was seen between rTMS and sham TMS using ALSFRS‐R and changes to muscle strength at 12 months. All three studies had significant methodological limitations including lack of information on random sequence generation or on allocation concealment, incomplete outcome data, high attrition and lack of intention‐to‐treat analyses. None of the trials reported any adverse events associated with the use of rTMS. In view of the significant methodological limitations, the review authors concluded that it would be premature to make any judgement on the short‐term or long‐term safety of rTMS. </p> </section> <section id="CD011776-sec-0049"> <h5 class="title">Therapeutic exercise</h5> <p><a href="./references#CD011776-bbs2-0004" title="Dal Bello‐HaasV , FlorenceJM . Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD005229.pub3] ">Dal Bello‐Haas 2013</a> identified two studies on the effects of exercise in people with MND, one of which (<a href="./references#CD011776-bbs2-0047" title="DroryVE , GoltsmanE , ReznikJG , MosekA , KorczynAD . The value of muscle exercise in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences2001;191(1‐2):133‐7. ">Drory 2001</a>), primarily investigated the effect of exercise on spasticity and is therefore also reported in the review for treatment of spasticity (<a href="./references#CD011776-bbs2-0001" title="AshworthNL , SatkunamLE , DeforgeD . Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004156.pub4] ">Ashworth 2012</a>). The focus of the exercise differed: one described endurance exercises; the other, resistive exercises. Both trials had small sample sizes (in total 43 participants) and the risk of bias of <a href="./references#CD011776-bbs2-0045" title="Dal Bello‐HaasVP , FlorenceJM , KloosAD , ScheirbeckerJ , LopateG , HayesSM , et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology2007;68(23):2003‐7. ">Dal Bello‐Haas 2007</a> was significantly lower than <a href="./references#CD011776-bbs2-0047" title="DroryVE , GoltsmanE , ReznikJG , MosekA , KorczynAD . The value of muscle exercise in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences2001;191(1‐2):133‐7. ">Drory 2001</a>, which had high attrition (30% at 3 months, with subsequent attrition so significant at 9 and 12 months that analyses could not be completed), no allocation concealment and no blinding. Outcome measures used, however, were similar in both studies and allowed pooling of data, which showed statistically significant improvement in disability (measured by ALSFRS) at 3 months, which was not sustained at 6 months. There were no statistical differences found in QoL, fatigue, or muscle strength and, importantly, no adverse events were reported. In people with MND, the lack of research evidence means that some clinicians discourage strengthening or aerobic exercise programmes. The safe range for therapeutic exercise is dependent on the extent of disease involvement — a weak muscle is more susceptible to overwork damage. This should be balanced, however, with the effects of cardiovascular deconditioning and disuse atrophy. The review authors concluded that the included studies were too small to determine to what extent strengthening exercises for people with ALS are beneficial or harmful. They therefore concluded that further studies are needed to determine the ideal exercise prescription for people with MND, in terms of both which exercise protocols are most beneficial or cause undue risks and whether there is a subset of people with MND who respond more positively to exercise. </p> </section> <section id="CD011776-sec-0050"> <h5 class="title">Multidisciplinary care</h5> <p>In the systematic review by <a href="./references#CD011776-bbs2-0007" title="NgL , KhanF . Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007425.pub2] ">Ng 2009</a>, the review authors found no randomised or quasi‐randomised controlled trials on multidisciplinary care for people with MND. Given the similar ethical concerns around designing such trials for treatment of pain, this was not unexpected. The authors considered observational, cohort and cross‐sectional studies with the understanding that contribution of such studies to best evidence synthesis would be limited. The review authors found five low‐ to very low‐quality observational studies that suggested very tentative evidence for QoL (mental health domains) without increasing healthcare costs, reduced hospitalisation (in outpatient settings), and improved disability (in inpatient settings). None of the studies reported any adverse effects attributable to multidisciplinary care. The authors concluded that whilst these findings were tentative, a gap in current research should not be interpreted as proof that multidisciplinary care is ineffective. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011776-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011776-sec-0051"></div> <section id="CD011776-sec-0052"> <h3 class="title" id="CD011776-sec-0052">Summary of main results</h3> <p>This overview draws together the findings from multiple Cochrane Systematic Intervention Reviews to give clinicians, policy makers and informed consumers a 'friendly front end' for data from a wide range of reviews. It has highlighted the lack of robust evidence on interventions to manage the symptoms resulting from MND. Very few large controlled trials have been undertaken for this condition in terms of symptom management. Three reviews were empty reviews; however, all three reported on non‐randomised controlled trial (non‐RCT) evidence and the remaining six included mostly one or two studies. One review on treatment for cramps included 20 studies, but many of these studies were not primarily designed to investigate treatment for cramps, the review did not fully report adverse events of these interventions, and seven trials reviewed cramps as adverse events. None of the reviews reported any adverse effects or events as a result of treatment apart from medications for cramps, which reported adverse events of riluzole (but did not report on adverse events of other interventions). Given the lack of robust evidence, it would be premature to judge the treatments as 'safe'. It is important to recognise that clinical trials may fail to show that a treatment is effective for several reasons other than that the drug is ineffective, for example insufficient statistical power, wrong choice of dose, insensitive outcome measures or inappropriate participant eligibility criteria. Therefore, a lack of evidence does not necessarily equate to ineffectiveness and should not override clinical judgement and discussion between a clinician and the person with MND. </p> <section id="CD011776-sec-0053"> <h4 class="title">By intervention/symptoms:</h4> <p>Comparisons were usual activities, usual care, or a placebo (inactive) treatment.</p> <section id="CD011776-sec-0054"> <h5 class="title">Interventions at the level of impairment</h5> <section id="CD011776-sec-0055"> <h6 class="title">Drug therapy for pain</h6> <p>There is no evidence for or against any drug therapy for pain for MND.</p> </section> <section id="CD011776-sec-0056"> <h6 class="title">Treatment for cramps</h6> <p>There is evidence from placebo‐controlled trials that tetrahydrocannabinol (THC) and memantine are probably ineffective for the treatment of cramps in MND (moderate‐quality evidence) and that vitamin E may have little or no effect (low‐quality evidence). The effects of L‐threonine, gabapentin, xaliproden, riluzole, and baclofen are uncertain, as the evidence is either very low quality or the trial specified the outcome but did not report numerical data. </p> </section> <section id="CD011776-sec-0057"> <h6 class="title">Treatment for spasticity</h6> <p>It is uncertain whether an endurance‐based exercise programme improves spasticity or quality of life (QoL) at 3 months compared with usual activities. The review did not evaluate other approaches, such as the use of baclofen. </p> </section> <section id="CD011776-sec-0058"> <h6 class="title">Mechanical ventilation for supporting respiratory function</h6> <p>Non‐invasive ventilation (NIV) probably improves median survival and quality of life in people with respiratory insufficiency and normal to moderately impaired bulbar function, compared to standard care, and improves QoL but not survival for people with poor bulbar function. </p> </section> <section id="CD011776-sec-0059"> <h6 class="title">Treatment for sialorrhoea</h6> <p>A single session of botulinum toxin type B injections to parotid and submandibular glands probably improves sialorrhoea and QoL at up to 4 weeks compared to placebo injections, but not at 8 or 12 weeks. The review did not evaluate other approaches as no trials were available. </p> </section> <section id="CD011776-sec-0060"> <h6 class="title">Enteral tube feeding for supporting nutrition</h6> <p>There is no RCT evidence for or against enteral tube feeding for supporting nutrition in MND. </p> </section> </section> <section id="CD011776-sec-0061"> <h5 class="title">Interventions at the level of activity and participation</h5> <section id="CD011776-sec-0062"> <h6 class="title">Repetitive transcranial magnetic stimulation (rTMS)</h6> <p>It is very uncertain whether or not rTMS improves disability or limitation in activity in MND compared to sham rTMS. </p> </section> <section id="CD011776-sec-0063"> <h6 class="title">Therapeutic exercise</h6> <p>Exercise may improve disability in MND at 3 months but not QoL compared to usual activities or usual care. </p> </section> <section id="CD011776-sec-0064"> <h6 class="title">Multidisciplinary care</h6> <p>There is no RCT evidence for or against multidisciplinary care in MND.</p> </section> </section> </section> <section id="CD011776-sec-0065"> <h4 class="title">By outcomes:</h4> <section id="CD011776-sec-0066"> <h5 class="title">Primary outcome – quality of life</h5> <p>The following interventions probably improve QoL in MND:</p> <p> <ul id="CD011776-list-0036"> <li> <p>NIV for survival;</p> </li> <li> <p>botulinum toxin type B injections for treatment of sialorrhoea 4 weeks after treatment.</p> </li> </ul> </p> <p>The following intervention probably does <i>not</i> improve QoL: </p> <p> <ul id="CD011776-list-0037"> <li> <p>botulinum toxin type B injections for treatment of sialorrhoea (moderate‐quality evidence) at 8 or 12 weeks. </p> </li> </ul> </p> <p>The following intervention may lead to little or no difference in QoL:</p> <p> <ul id="CD011776-list-0038"> <li> <p>endurance‐based exercise programme for spasticity treatment or resistive exercise programme (low‐quality evidence) at 3 months. </p> </li> </ul> </p> <p>It is not known if the following interventions improve QoL:</p> <p> <ul id="CD011776-list-0039"> <li> <p>drug therapy for pain;</p> </li> <li> <p>drug therapy for cramps: THC, memantine, riluzole, vitamin E, L‐ threonine, gabapentin, xaliproden, riluzole, and baclofen; </p> </li> <li> <p>enteral tube feeding for nutrition;</p> </li> <li> <p>rTMS;</p> </li> <li> <p>multidisciplinary care.</p> </li> </ul> </p> </section> <section id="CD011776-sec-0067"> <h5 class="title">Secondary outcomes</h5> <p><b>Impairment</b> – refer to individual interventions at the level of impairment above. </p> <p><b>Activity and participation</b> as measured by ALSFRS </p> <p>The following interventions may improve level of activity/reduce disability (low‐quality evidence): </p> <p> <ul id="CD011776-list-0040"> <li> <p>resistive exercise programme at 3 months.</p> </li> </ul> </p> <p>It is uncertain whether or not the following interventions improve level of activity or reduce disability because the quality of evidence is very low: </p> <p> <ul id="CD011776-list-0041"> <li> <p>endurance‐based exercise programme for treatment of spasticity at 3 months;</p> </li> <li> <p>rTMS.</p> </li> </ul> </p> <p>It is not known if the following interventions improve level of activity/reduce disability:</p> <p> <ul id="CD011776-list-0042"> <li> <p>NIV;</p> </li> <li> <p>botulinum toxin type B injections for treatment of sialorrhoea;</p> </li> <li> <p>drug therapy for pain;</p> </li> <li> <p>drug therapy for cramps: THC, memantine, riluzole, vitamin E, L‐threonine, gabapentin, xaliproden, riluzole, and baclofen; </p> </li> <li> <p>enteral tube feeding for nutrition;</p> </li> <li> <p>multidisciplinary care.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011776-sec-0068"> <h3 class="title" id="CD011776-sec-0068">Overall completeness and applicability of evidence</h3> <p>This overview sought to determine the efficacy of interventions used for the relief of symptoms at the level of impairment, activity and participation in people with MND. Only Cochrane Systematic Reviews with participants who had MND were included in this overview. Due to the heterogeneity of the interventions, we were unable to perform any mathematical or statistical direct or indirect comparisons across reviews. Two reviews (treatment of spasticity and therapeutic exercise) had an overlap of included studies and there were many other symptoms in MND (such as cognitive and behavioural impairment and pseudobulbar emotional lability), which were not covered at all in this overview. Protocols for Cochrane Systematic Reviews of diaphragm pacing in ALS (<a href="./references#CD011776-bbs2-0019" title="MaguireC , McDermottC , HindD , RadunovicA , ShawPJ . Diaphragm pacing systems for amyotrophic lateral sclerosis / motor neuron disease. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD011222] ">Maguire 2014</a>) and treatment of fatigue (<a href="./references#CD011776-bbs2-0027" title="YoungCA , GibbonsC , PagniniF , FriedeT . Treatment for fatigue in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD011005] ">Young 2014</a>) have been published and reviews are in development, There was a relative lack of QoL data. Most of the trials were too small for reliable adverse event reporting. </p> </section> <section id="CD011776-sec-0069"> <h3 class="title" id="CD011776-sec-0069">Quality of the evidence</h3> <p>It is current policy for the Cochrane Library to update reviews as new evidence likely to change conclusions emerges. All of the included systematic reviews have been updated within 5 years of publication where there has been such evidence. Conclusions of the reviews are therefore mostly reflective of current research findings. All the systematic reviews were of robust methodological quality although three were empty, hence many of the methodological quality criteria were not applicable and a conclusion is that there is no high‐quality evidence for these areas. All included Cochrane Systematic Reviews used a standard quality assessment tool (Cochrane 'Risk of bias' tool), hence there was a uniformity in assessment of bias. Conflicts of interest were clear within the reviews themselves but not routinely reported for the included studies within the included systematic reviews. It would helpful for this information to be presented in the reviews to allow for determination of potential biases in outcomes and conclusions drawn. Updated Cochrane methodology now mandates the reporting of conflicts from primary studies where available. </p> <p>Of the Cochrane Systematic Reviews with included studies, most had small numbers of studies (usually one or two only) each with small numbers of participants. There was imprecision of the data for measures of effect in many of the trials. High attrition rates were also common and intention‐to‐treat analysis was not always applied. Blinding of participants was difficult with most of the interventions; and outcome assessors were also often not blinded. Where participants and outcome assessors were clearly blinded (<a href="./references#CD011776-bbs2-0009" title="YoungCA , EllisC , JohnsonJ , SathasivamS , PihN . Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006981.pub2] ">Young 2011</a>), by 12 weeks 70% of investigators and 90% of participants guessed treatment allocation correctly, suggesting that despite excellent attempts to maintain blinding, the double‐blind was not preserved. Regardless, the methodological quality of almost all the studies could have been improved with blinding of outcome assessors. Additionally, there was significant heterogeneity of intervention within each review and outcomes also varied widely. None of the studies addressed cost‐benefits, nor the role of caregivers and their needs. </p> </section> <section id="CD011776-sec-0070"> <h3 class="title" id="CD011776-sec-0070">Potential biases in the overview process</h3> <p>All overviews are limited by the risks of bias of the included Cochrane Systematic Reviews and their included studies. We limited systematic review inclusions and extraction of data to Cochrane Systematic Reviews. It is possible that the Cochrane Systematic Reviews may not have sought unpublished or ongoing studies via trials' registries as this was not standard practice at the time of publication of many of these reviews. We did not seek additional information from authors of the included studies. The high Assessment of Multiple Systematic Reviews (AMSTAR) scores for the Cochrane reviews were reassuring for the quality of the reviews. However, the use of GRADE criteria introduced an element of subjective judgement although this is now widely accepted as a quality tool. It was made more challenging as the overview primarily assessed the included reviews rather than the original studies, and review authors may assess and report study quality in different ways. Judgement can be open to interpretation. We made the decision to downgrade studies twice based on small sample sizes, inadequately powered to detect an effect, which was harsher than the decision of the authors of the original reviews. We also decided that a single, albeit high‐quality, study at low risk of bias was at best able to provide moderate‐quality evidence where further research still had a likelihood of changing the estimate of effect. </p> <p>LN, FK and CY are authors of included systematic reviews. Two overview authors, at least one of whom was not an author of the original included reviews, independently assessed the methodological quality of each review included in the overview. </p> </section> <section id="CD011776-sec-0071"> <h3 class="title" id="CD011776-sec-0071">Agreements and disagreements with other studies or reviews</h3> <p>To the best of our knowledge, there are no other systematic overviews on interventions to manage symptoms in people with MND. Evidence‐based practice for MND should include a) integration of best available scientific evidence, b) clinical expertise, judgement, and agreement, and c) the incorporation of the values and beliefs of people with MND. There is currently a gap between the available evidence, clinical practice, and agreement between clinicians and incorporation of patient values in the treatment of people with MND (<a href="./references#CD011776-bbs2-0043" title="CiceroneKD . Evidence based practice and limits of rational rehabilitation. Archives of Physical Medicine and Rehabilitation2005;86:1073‐74. ">Cicerone 2005</a>). </p> <p>Whilst RCTs remain the 'gold standard' for determining the effectiveness of interventions, concerns have been raised about the application of RCTs in complex interventions such as rehabilitation or multidisciplinary care (<a href="./references#CD011776-bbs2-0043" title="CiceroneKD . Evidence based practice and limits of rational rehabilitation. Archives of Physical Medicine and Rehabilitation2005;86:1073‐74. ">Cicerone 2005</a>). For such complex interventions, an alternative to RCTs may be the use of an observational approach — the Practice Clinical Trial or Clinical Practice Improvement (CPI) method that acquires prospective or retrospective data without disrupting the natural milieu of treatment (<a href="./references#CD011776-bbs2-0051" title="GassawayJ , HornSD , DeJongG , RandallJ , SmoutMS . Applying the clinical practice improvement approach to stroke rehabilitation: Methods used and baseline results. Archives of Physical Medicine and Rehabilitation2005;86(12 Suppl 2):S16‐S33. ">Gassaway 2005</a>). These types of studies, however, are not generally included within Cochrane reviews. Cochrane Systematic Reviews that in the future include non‐randomised evidence, graded for quality, may add to the volume of evidence in this overview, but may make quality judgements harder. </p> <p>Even with the study of effects of simple interventions or discrete outcomes where RCTs are best suited, there are a number of logistical and ethical reasons that makes treatment in MND particularly challenging to study. MND is a relatively rare condition, heterogenous in clinical presentation and manifestations, and results in a rapidly disabling population with high mortality rates. People with MND often prefer to participate in disease‐modifying pharmaceutical trials that might slow disease progression over other trials (<a href="./references#CD011776-bbs2-0045" title="Dal Bello‐HaasVP , FlorenceJM , KloosAD , ScheirbeckerJ , LopateG , HayesSM , et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology2007;68(23):2003‐7. ">Dal Bello‐Haas 2007</a>). Attrition is particularly common, especially in trials requiring longer follow‐up, as participants may have difficulty attending clinic for follow‐up due to respiratory and mobility issues, rapid disease deterioration resulting in mechanical ventilation or death, long distances to travel to the clinic for follow‐up, and fatigue (<a href="./references#CD011776-bbs2-0047" title="DroryVE , GoltsmanE , ReznikJG , MosekA , KorczynAD . The value of muscle exercise in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences2001;191(1‐2):133‐7. ">Drory 2001</a>). </p> <p>Because of the nature of MND, it is also difficult to research clinically accepted or recommended practice, regardless of the level of evidence supporting the practice. It would not be ethical, for example, to design a placebo‐controlled trial for treatment of pain in MND or to withhold multidisciplinary care where such care is available. It is, therefore, highly likely that there will never be RCTs available in these areas. Similarly, where there is some evidence of benefit from a single RCT, such as in NIV, it is unlikely that further RCTs of NIV in unselected cohorts of people with MND would occur. Even when there are no RCTs available but there is non‐RCT evidence showing weak survival advantage, such as in the case of enteral tube feeding, it is probably unlikely that RCTs will be conducted. Regardless of the evidence available, local practices also vary considerably, for cultural, financial or other reasons. Assisted ventilation for example can be provided with invasive (tracheostomy ventilation) or non‐invasive means. Whilst tracheostomy ventilation in MND is not encouraged in Europe and North America (<a href="./references#CD011776-bbs2-0035" title="BorasioGD , ShawPJ , HardimanO , LudolphAC , Sales LuisM , SilaniV . Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders2001;2(3):159‐64. ">Borasio 2001</a>; <a href="./references#CD011776-bbs2-0080" title="YamaguchiM , HideakiH , KunikoH . Ventilatory support in Japan: A new life with ALS and a positive approach to living with the disease. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders2001;2(4):209‐11. ">Yamaguchi 2001</a>), it is the predominant form of ventilation offered to people in Japan, where the cost is fully covered by the government and medical insurance (<a href="./references#CD011776-bbs2-0056" title="KawataA , MizoguchiK , HayashiH . A nationwide survey of ALS patients on tracheostomy positive pressure ventilation (TPPV) who developed a totally locked‐in state (TLS) in Japan. Rinsho Shinkeigaku2008;48(7):476‐80. ">Kawata 2008</a>). </p> <p>Another issue relating to clinical trials is the choice of outcome measures. Due to the widespread use of ALSFRS‐R, when outcomes at the level of activity limitation are measured, trials commonly use ALSFRS‐R, which allows for pooling of data. QoL is an important outcome measure for people with MND. QoL is a broad concept however, and it is not easily incorporated in a single quantitative statistically valid outcome measurement. Furthermore the measurement has no anchor and people with MND often report a high QoL, persisting throughout their disease due to shifting expectations and to reprioritisation factors contributing to QoL (<a href="./references#CD011776-bbs2-0070" title="SimmonsZ . Patient‐perceived outcomes and quality of life in ALS. Neurotherapeutics2015;12(2):394‐402. ">Simmons 2015</a>). Many outcome measures for health‐related QoL are generic (e.g. SF‐36), not fully validated for MND and limited by floor effects (<a href="./references#CD011776-bbs2-0055" title="JenkinsonC , HobartJ , ChandolaT , FitzpatrickR , PetoV , SwashM . Use of the short form health survey (SF‐36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions. Journal of Neurological Sciences2002;249:178‐83. ">Jenkinson 2002</a>; <a href="./references#CD011776-bbs2-0081" title="YoungCA , TedmanBM , WilliamsIR . Disease progression and perceptions of health in patients with motor neurone disease. Journal of Neurological Sciences1995;129(Suppl):50‐3. ">Young 1995</a>). Although measures specific for MND, such as the ALSAQ‐40, have since been developed for use, they have yet to be widely taken up. Some are heavily weighted towards physical function (e.g. ALSAQ‐40) and do not include an existential element (perception of purpose, meaning of life, capacity for personal growth) relevant for persons with MND (<a href="./references#CD011776-bbs2-0037" title="BrombergMB . Quality of life in amyotrophic lateral sclerosis. Physical Medicine and Rehabilitation Clinics of North America2008;19(3):591‐605. ">Bromberg 2008</a>). Other measures in this population include the direct‐weight version of the Schedule of the Evaluation of Individual Quality of Life (SEIQoL‐DW) (<a href="./references#CD011776-bbs2-0053" title="HickeyAM , BuryG , O'BoyleCA , BradleyF , O'KellyFD , ShannonW . A new short form individual quality of life measure (SEIQoL‐DW): Application in a cohort of individuals with HIV/AIDS. BMJ (Clinical research edition)1996;313(7048):29‐33. ">Hickey 1996</a>), which can be used for both people with MND and their caregivers, but this scale is time intensive (<a href="./references#CD011776-bbs2-0061" title="MountainLA , CampbellSE , SeymourDG , PrimroseWR , WhyteMI . Assessment of individual quality of life using the SEIQoL‐DW in older medical patients. QJM : Monthly Journal of the Association of Physicians2004;97(8):519‐24. ">Mountain 2004</a>), and does not allow comparison between people. The World Health Organization (WHO) pioneered the development of QoL measures with a more global view (WHOQOL and WHOQOL‐BREF) (<a href="./references#CD011776-bbs2-0077" title="The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Social Science &amp; Medicine1998;46(12):1569‐85. ">WHOQOL 1998a</a>; <a href="./references#CD011776-bbs2-0078" title="The WHOQOL Group. Development of the World Health Organization WHOQOL‐BREF quality of life assessment. Psychological Medicine1998;28(3):551‐8. ">WHOQOL 1998b</a>). More recently, a modified version of the McGill questionnaire, which also has more global elements, was validated as an ALS‐specific QoL questionnaire (the ALSSQOL) (<a href="./references#CD011776-bbs2-0069" title="SimmonsZ , FelgoiseSH , BremerBA , WalshSM , HuffordDJ , BrombergMB , et al. The ALSSQOL: balancing physical and nonphysical factors in assessing quality of life in ALS. Neurology2006;67(9):1659‐64. ">Simmons 2006</a>), and a shortened version (ALSSQOL‐R) has been validated through multicentre study (<a href="./references#CD011776-bbs2-0049" title="FelgoiseSH , RodriguezJL , BremerBA , WalshSM , StephensHE , HorowitzMD , et al. Validation of the ALS specific quality of life‐revised measure (ALSSQOL‐R). 18th International Symposium on ALS/MND; 2007 Dec 1‐3; Toronto, Ontario, Canada. 2007. ">Felgoise 2007</a>). In general, the overall self‐perceived well‐being of a person with MND is determined by wide‐ranging factors including physical, psychological, existential, religious, and financial, etc. and a global instrument such as WHOQOL‐BREF, SEIQoL‐DW, or ALSSQOL‐R may be used (<a href="./references#CD011776-bbs2-0070" title="SimmonsZ . Patient‐perceived outcomes and quality of life in ALS. Neurotherapeutics2015;12(2):394‐402. ">Simmons 2015</a>). When assessing the impact of a very specific therapeutic intervention, however, global QoL instruments will likely be insensitive and therefore a more specific instrument that is based on health‐related QoL should be chosen (<a href="./references#CD011776-bbs2-0070" title="SimmonsZ . Patient‐perceived outcomes and quality of life in ALS. Neurotherapeutics2015;12(2):394‐402. ">Simmons 2015</a>). For example, NIV improves sleep quality but as the person deteriorates in health, they may experience loss of relationships or financial difficulties which would affect global QoL. Not surprisingly, therefore, it was found that NIV improved Sleep Apnoea Quality of Life Index but not SF‐36. </p> </section> </section> </section> <div class="tables-list"> <div class="table"> <table data-id="CD011776-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">AMSTAR tool: quality assessment criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Specific requirements</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Was an 'a priori' design provided?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The research question and inclusion criteria should be established before the conduct of the review. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Was there duplicate study selection and data extraction?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. Was a comprehensive literature search performed?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least two electronic sources should be searched. The report must include years and databases used (e.g. CENTRAL, Embase, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialised registers, or experts in the particular field of study, and by reviewing the references in the studies found. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language, etc. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. Was a list of studies (included and excluded) provided?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A list of included and excluded studies should be provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Were the characteristics of the included studies provided?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analysed e.g. age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7. Was the scientific quality of the included studies assessed and documented?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'A priori' methods of assessment should be provided (e.g. for effectiveness studies if the author(s) chose to include only randomised, double‐blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. Was the scientific quality of the included studies used appropriately in formulating conclusions? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The results of the methodological rigour and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9. Were the methods used to combine the findings of studies appropriate?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e. Chi² for homogeneity, I²). If heterogeneity exists a random‐effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e. is it sensible to combine?). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. Was the likelihood of publication bias assessed?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An assessment of publication bias should include a combination of graphical aids (e.g. funnel plot, other available tests) and/or statistical tests (e.g. Egger regression test). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. Was the conflict of interest stated?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Each criterion judged as 'Yes' (score one point), 'No' (score no point), 'Can't answer' (score no point) or 'Not applicable' (score one point). Total score summed out of a maximum 11 points. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">AMSTAR tool: quality assessment criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011776-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of excluded reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reason for exclusion</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0010" title="Abdul WahidSF , LawZK , LaiNM , IsmailNA , Azman AliR . Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011742] ">Abdul Wahid 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> <p>Disease‐modifying treatments (since published in CENTRAL, Issue 10, 2016 in the Cochrane Library) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0019" title="MaguireC , McDermottC , HindD , RadunovicA , ShawPJ . Diaphragm pacing systems for amyotrophic lateral sclerosis / motor neuron disease. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD011222] ">Maguire 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0027" title="YoungCA , GibbonsC , PagniniF , FriedeT . Treatment for fatigue in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD011005] ">Young 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0023" title="PastulaDM , MooreDH , BedlackRS . Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD005225.pub3] ">Pastula 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0012" title="BeauverdM , MitchellJD , WokkeJHJ , BorasioGD . Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD002064.pub3] ">Beauverd 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0026" title="YiZM , LiuF , ZhaiSD , BelshJ , ZhanSY , SchiffmanP . Pharmacological interventions for improving respiratory function in amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD010030] ">Yi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0020" title="MillerRG , MitchellJD , MooreDH . Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD001447.pub3] ">Miller 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0013" title="BenatarM , KurentJ , MooreDH . Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006153.pub2] ">Benatar 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0015" title="BongioanniP , BorasioGD , OliverD , TramontiF , RomagnoliA , KapitzaKP . Methods for informing people with amyotrophic lateral sclerosis/motor neuron disease of their diagnosis. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD007593] ">Bongioanni 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> <p>Not related to treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0025" title="SathasivamS , Addison‐JonesR , MillerRG , MooreDH , YoungCA . Minocycline for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD006840] ">Sathasivam 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0021" title="OrrellRW , LaneRJM , RossM . Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002829.pub4] ">Orrell 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0016" title="DianaA , SogosV , BongioanniP , MillerRG , MooreDH . Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD006049] ">Diana 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol only</p> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0014" title="BongioanniP , RealiC , SogosV . Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004302.pub2] ">Bongioanni 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disease‐modifying treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0011" title="AnnaneD , OrlikowskiD , ChevretS . Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD001941.pub3] ">Annane 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results for people with MND are not reported separately</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0024" title="PayneC , WiffenPJ , MartinS . Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD008427.pub2] ">Payne 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies included in this review for people with MND are already covered in the included studies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0018" title="LeeCN . Reviewing evidences on the management of patients with motor neuron disease. Hong Kong Medical Journal2012;18:48‐55. ">Lee 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not a systematic review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0017" title="GoodP , RichardR , SyrmisW , Jenkins‐MarshS , StephensJ . Medically assisted nutrition for adult palliative care patients. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD006274.pub3] ">Good 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies included in this review for people with MND are already covered in the included studies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0022" title="PaoloB , NicolaT , AgataL , AndreaG , AntonelloN , VincenzoS . A review of options for treating sialorrhea in amyotrophic lateral sclerosis. Respiratory Care2015;60(3):446‐54. ">Paolo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not a systematic review</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of excluded reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011776-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author/year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Date assessed as up to date</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary and secondary outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Limitations*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0003" title="BrettschneiderJ , KurentJ , LudolphA . Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD005226.pub3] ">Brettschneider 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any drug therapy, given by any route, in any dose, administered to relieve pain in ALS/MND </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated but assumed one intervention to another or to placebo or no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (impairment):</p> <p> <ul id="CD011776-list-0008"> <li> <p>Pain relief (after 24 hours) (VAS or any other validated scales)</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0009"> <li> <p>Pain relief (after 7 days)</p> </li> </ul> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0002" title="BaldingerR , KatzbergHD , WeberM . Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD004157.pub2] ">Baldinger 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feb 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any drug therapy (oral, subcutaneous or intravenous) or physical treatment which potentially relieves cramps in ALS/MND </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated but assumed one intervention to another or to placebo or no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>impairment</i>): </p> <p> <ul id="CD011776-list-0010"> <li> <p>Reduction in subjective global impression of muscle cramp burden measured through VAS </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0011"> <li> <p>Cramp intensity/number of cramps in 24 hours preceding assessment by VAS</p> </li> <li> <p>Ratio of participants experiencing cramps to total number of participants (in studies where cramps were assessed as adverse events) </p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0012"> <li> <p>QoL</p> </li> </ul> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0001" title="AshworthNL , SatkunamLE , DeforgeD . Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004156.pub4] ">Ashworth 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Physical therapy/physiotherapy</p> <p>2) Modalities (e.g. heat, cold, vibration, electrical stimulation)</p> <p>3) Non‐prescription medications (e.g. vitamins, herbals, diet supplements)</p> <p>4) Chemical neurolysis (e.g. phenol blocks, botulinum toxin)</p> <p>5) Surgical intervention (e.g. intrathecal pumps, tenotomy, dorsal rhizotomy)</p> <p>6) Alternative therapies (e.g. reflexology, aromatherapy, relaxation techniques)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated but assumed one intervention to another or to placebo or no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>impairment</i>): </p> <p> <ul id="CD011776-list-0013"> <li> <p>Reduction in spasticity at three months as measured by Ashworth (or modified Ashworth) spasticity scale </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0014"> <li> <p>Reduction in spasticity based on history (e.g. spasm frequency score), physical examination (e.g. reflex score) or physiology (e.g. pendulum test) </p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0015"> <li> <p>Disability/activity limitation (e.g. functional independence measure)</p> </li> <li> <p>QoL</p> </li> </ul> </p> <p><i>Adverse events</i> </p> <p><i>Cost‐effectiveness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0008" title="RadunovicA , AnnaneD , RafiqMK , MustfaN . Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD004427.pub3] ">Radunovic 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>May 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All forms of non‐invasive ventilation (NIV) and tracheostomy assisted ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No intervention or best standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p> <ul id="CD011776-list-0016"> <li> <p>Survival as assessed by pooled hazards ratio using life table/Cox regression methods to combine disparate periods of observation from all studies </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD011776-list-0017"> <li> <p>Survival at 1 month and 6 months and longer</p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0018"> <li> <p>Function – such as ALSFRS</p> </li> <li> <p>QoL</p> </li> </ul> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0009" title="YoungCA , EllisC , JohnsonJ , SathasivamS , PihN . Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006981.pub2] ">Young 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>September 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Any drug treatment administered via any route</p> <p>2) Injection of botulinum toxin in parotid and/or submandibular glands</p> <p>3) Radiotherapy to the salivary glands</p> <p>4) Surgical techniques, for example the ligation of parotid and submandibular salivary ducts </p> <p>5) Other treatments identified in the literature such as complementary therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One intervention to another or to placebo or no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>impairment</i>): </p> <p> <ul id="CD011776-list-0019"> <li> <p>Subjective improvement in sialorrhoea</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ol id="CD011776-list-0020"> <li> <p>Reduction in amount of saliva production using an objective measure such as weight of swabs or amount of tissue used </p> </li> </ol> </p> <p><i>Activity and participation</i> </p> <p> <ol id="CD011776-list-0021"> <li> <p>QoL</p> </li> </ol> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0006" title="KatzbergHD , BenatarM . Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD004030.pub3] ">Katzberg 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>September 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placement of percutaneous endoscopic gastrostomy (PEG) or other tube feeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No feeding tube and continued oral intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p> <ul id="CD011776-list-0022"> <li> <p>Survival time</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ol id="CD011776-list-0023"> <li> <p>Quantitative index of change in nutritional status (e.g. weight change, change in body mass index, other nutritional markers such as pre‐albumin level) </p> </li> </ol> </p> <p><i>Activity and participation</i> </p> <p> <ol id="CD011776-list-0024"> <li> <p>QoL</p> </li> </ol> </p> <p><i>Adverse events (safety of PEG)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0005" title="FangJ , ZhouM , YangM , ZhuC , HeL . Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD008554.pub3] ">Fang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Repetitive transcranial magnetic stimulation (rTMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No intervention or sham rTMS or physiotherapy or medications or different methods of applications of rTMS such as high‐frequency (&gt; 1 Hz) compared to low frequency (≤ 1 Hz) rTMS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>activity and participation</i>): </p> <p> <ul id="CD011776-list-0025"> <li> <p>Disability or limitation in activity as measured by ALSFRS‐R (6 months)</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0026"> <li> <p>Changes to muscle strength as measured by Manual Muscle Testing (1 and 6 months or longer) </p> </li> <li> <p>Changes to fatigue as measured by Fatigue Severity Scale (1 and 6 months or longer)</p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0027"> <li> <p>Disability or limitation in activity as measured by ALSFRS‐R (12 months)</p> </li> </ul> </p> <p><i>Adverse events</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0004" title="Dal Bello‐HaasV , FlorenceJM . Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD005229.pub3] ">Dal Bello‐Haas 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressive resistance or strengthening exercise and endurance or aerobic exercise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No exercise or standard rehabilitation management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome (<i>activity and participation</i>): </p> <p> <ul id="CD011776-list-0028"> <li> <p>Improvement in functional ability, decrease in disability or reduction in rate of decline as measured by ALSFRS‐R or other validated outcome measures (3 months) </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0029"> <li> <p>Decrease in fatigue</p> </li> <li> <p>Change in rate of decline of muscle strength</p> </li> <li> <p>Change in rate of decline of aerobic endurance</p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0030"> <li> <p>Improvement in psychological status or QoL</p> </li> </ul> </p> <p><i>Adverse events</i> </p> <p>(all at 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0062" title="NgL , TalmanP , KhanF . Motor neurone disease: disability profile and service needs in an Australian cohort. International Journal of Rehabilitation Research2011;34(2):151‐9. ">Ng 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>July 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multidisciplinary care as defined by any intervention delivered by two or more allied health disciplines (includes nursing physiotherapy, occupational therapy, speech therapy, etc.), directed by a physician, designed to be patient‐centred and aimed at maximising activity and participation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lower level or different type of intervention such as “routinely available local services” or “minimal intervention” (such as information only), waiting list conditions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcomes (<i>activity and participation</i>): </p> <p> <ul id="CD011776-list-0031"> <li> <p>Improvement in QoL</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p><i>Impairment</i> </p> <p> <ul id="CD011776-list-0032"> <li> <p>Improvement in Impairment (e.g. FVC)</p> </li> </ul> </p> <p><i>Activity and participation</i> </p> <p> <ul id="CD011776-list-0033"> <li> <p>Improvement in functional ability (e.g. ALSFRS)</p> </li> <li> <p>Participation and environmental or personal context (e.g. caregiver strain index)</p> </li> </ul> </p> <p><i>Survival</i> </p> <p><i>Hospitalisation such as readmission and hospital length of stay</i> </p> <p><i>Adverse events</i> </p> <p><i>Cost‐effectiveness of care</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>*Not clearly covered by AMSTAR assessment</p> <p>Abbreviations: ALSFRS: Amyotrophic Lateral Sclerosis Functional Rating Scale; FVC: forced vital capacity; QoL: quality of life; RCT: randomised controlled trial; VAS: visual analogue scale </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011776-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AMSTAR ratings of included reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author/year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Brettschneider 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baldinger 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ashworth 2012</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radunovic 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Young 2011</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Katzberg 2011</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fang 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dal Bello‐Haas 2013</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ng 2011</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'A priori' design for the systematic review provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duplicate study selection and data extraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comprehensive literature search</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Search for studies regardless of their publication type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>List of included and excluded studies provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Characteristics of included studies provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scientific quality of included studies assessed and documented</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Scientific quality of included studies used appropriately in formulating conclusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appropriate methods used to combine study findings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Likelihood of publication bias assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conflict of interest stated for both the systematic review and included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total score (n/11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Y = Yes – criteria met (score one point), N= No – criteria not met (score 0 points), CA = Can't answer (score 0 points), NA= not applicable (score 1 point) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">AMSTAR ratings of included reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011776-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Overview of reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Interventions at the level of impairment/symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Drug therapy for pain</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author/year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes in the review for which data are available</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of the evidence (GRADE) for reported efficacy outcomes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0003" title="BrettschneiderJ , KurentJ , LudolphA . Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD005226.pub3] ">Brettschneider 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Treatment for cramps</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0002" title="BaldingerR , KatzbergHD , WeberM . Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD004157.pub2] ">Baldinger 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 RCTs</p> <p>N = 4012<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tetrahydrocannabinol (THC), vitamin E, baclofen, riluzole, L‐threonine, xaliproden, memantine, gabapentin, </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p> <ul id="CD011776-list-0034"> <li> <p>Memantine, tetrahydrocannabinol (THC) are probably ineffective (moderate‐quality evidence)</p> </li> <li> <p>vitamin E may be ineffective</p> </li> <li> <p>It is uncertain whether L‐threonine, gabapentin, xaliproden, riluzole, or baclofen are effective (very low quality evidence, or data not reported) </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ol id="CD011776-list-0035"> <li> <p>Cramp intensity/number of cramps in 24 hours preceding assessment by VAS – no statistical difference for THC (not assessed in other studies) </p> </li> <li> <p>Ratio of participants experiencing cramps to total number of participants (in studies where cramps were assessed as adverse events) – not an outcome of interest in this review </p> </li> <li> <p>QoL – not measured</p> </li> <li> <p>Adverse events</p> </li> </ol> </p> <p>Adverse effects for riluzole 100 mg/day – increased asthenia, spasticity, increase in liver enzymes, impaired respiratory function, and elevation in blood pressure </p> <p>Adverse effects for vitamin E, baclofen, gabapentin, L‐threonine, xaliproden, memantine and THC not stated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low:</p> <p>L‐threonine – 3 studies with very high risk of bias (very small sample sizes, unclear randomisation process and allocation concealment, incomplete outcome data) </p> <p>Baclofen – 1 study with high risk of bias and very small sample sizes; subjective impression of cramps listed as an outcome but data not reported </p> <p>Low:</p> <p>Vitamin E – 1 study with clear randomisation, allocation concealment, and blinding, but high risk of selective reporting given change in protocol and no information given on number of participants at 12 months or date of last examination </p> <p>Moderate:</p> <p>THC – 1 study with low risk of bias</p> <p>Memantine – 1 study with low risk of bias</p> <p>Outcome not reported:</p> <p>Riluzole – 3 studies, 2 of which had high risk of bias due to incomplete reporting and 1 at low risk of bias; cramps listed as an outcome but data not reported </p> <p>Xaliproden – 2 studies with low risk of bias; cramps an outcome but results not given</p> <p>Gabapentin – 1 study with low risk of bias. Cramps an outcome but data not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Treatment for spasticity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0001" title="AshworthNL , SatkunamLE , DeforgeD . Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004156.pub4] ">Ashworth 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT N = 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endurance exercises</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Usual activities”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p>Reduction in spasticity in favour of treatment group (mean reduction of −0.43, 95% CI −1.03 to 0.17 in intervention vs increase of 0.25, 95% CI −0.46 to 0.96 in control) </p> <p>Secondary outcomes:</p> <p>No statistically significant differences between exercise and placebo groups in muscle strength (manual muscle testing, fatigue (fatigue severity scale) and QoL (SF‐36). No adverse effects reported. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low:<br/> 1 trial with high risk of bias, unclear randomisation, no allocation concealment, no blinding, 50% attrition by 6 months. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Mechanical ventilation for supporting respiratory function</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0008" title="RadunovicA , AnnaneD , RafiqMK , MustfaN . Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD004427.pub3] ">Radunovic 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT N = 41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐invasive ventilation (NIV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Standard care"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:</p> <p>Median survival was 48 days longer (219 days vs 171 days) compared to the standard care group (estimated 95% CI 12 to 91 days, P = 0.0062). In subgroup analyses, median survival of subgroup with good or moderately impaired bulbar function was significantly different in favour of NIV group (P = 0.0059) with survival 205 days longer than standard care participants (median 216 in NIV group vs 11 days in standard care group). In participants with poor bulbar function, NIV did not confer survival advantage (P = 0.92). </p> <p>Secondary outcomes:</p> <p>1) QoL – significant benefit in favour of NIV in <i>maintenance</i> of QoL in good or moderately impaired bulbar function subgroup (P = 0.0017 SF‐35 Health Survey mental component summary score; P = 0.0013 mean symptoms domain of the sleep apnoea QoL index) and significant benefit in favour of NIV in subgroup of poor bulbar function in <i>improvement</i> in mean symptoms domain of the sleep apnoea QoL index but not in the SF‐36 Health Survey mental component summary score </p> <p>2) Function – such as ALSFRS – not measured</p> <p>3) No adverse events reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate:<br/> 1 trial with low risk of bias (clear random sequence generation, adequate allocation concealment, data was complete and there was no selective reporting or other bias. Blinding of participants was not possible and it was unclear if outcome assessors were blinded). </p> <p>Originally 2 RCTs were identified with a total of 54 participants; however, 1 was a pilot study with no study protocol and incomplete data (data available for 6 out of the 13 participants) and was therefore not included in meta‐analysis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Treatment for sialorrhoea</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0009" title="YoungCA , EllisC , JohnsonJ , SathasivamS , PihN . Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006981.pub2] ">Young 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 RCT N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Botulinum toxin B injection into parotid and submandibular glands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo (normal saline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:<br/> Subjective improvement in sialorrhoea at week 2 and 4 in favour of treatment group (treatment 82% improved, placebo 38%, P &lt; 0.05 at week 2; treatment 90% improved, placebo 44%, P &lt; 0.05 at week 4. No statistically significant difference at week 8 or 12. </p> <p>Secondary outcomes:</p> <p>1) Volume of saliva produced as measured with funnel and tube over 5 min – significant difference in favour of treatment group at week 2 (treatment 0.07, SD 0.2; placebo 0.84, SD 0.8, P &lt; 0.05) and week 4 (treatment 0.02, SD 0.04; placebo 0.97, SD 0.5, P &lt; 0.05), but not at week 8 or 12. </p> <p>2) QoL as measured by clinicians' assessment of marked improvement using the SEIQOL‐DW showed a statistically significant difference from baseline with botulinum toxin but not placebo at week 2 but not at later time points </p> <p>3) No adverse events reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate:<br/> 1 trial, small sample size but low risk of bias. By 12 weeks, 70% of investigators and 90% of participants guessed treatment allocation correctly suggesting that despite excellent attempts to maintain blinding, the double‐blind was not preserved. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Enteral tube feeding for supporting nutrition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0006" title="KatzbergHD , BenatarM . Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD004030.pub3] ">Katzberg 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Interventions at the level of activity and participation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Repetitive transcranial magnetic stimulation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0005" title="FangJ , ZhouM , YangM , ZhuC , HeL . Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD008554.pub3] ">Fang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 RCTs, N = 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Repetitive transcranial magnetic stimulation (rTMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham rTMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcomes: not measured.</p> <p>Secondary outcomes:</p> <p>No statistical difference in disability or limitation in activity as measured by ALSFRS‐R (12 months) or muscle strength. </p> <p>Changes to fatigue not measured.</p> <p>No adverse effects reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low:<br/> All trials of poor methodological quality (2 of the 3 were missing raw numerical data), insufficiently homogenous to pool results, small sample sizes and high attrition (30% to 40%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Therapeutic exercise</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0004" title="Dal Bello‐HaasV , FlorenceJM . Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD005229.pub3] ">Dal Bello‐Haas 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 RCTs, N = 43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exercise (endurance or resistance)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>“Usual activities” or “usual care” (stretching exercise)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary outcome:<br/> Significant improvement in disability or limitation in activity as measured by ALSFRS in favour of exercise groups (3 months) (MD 3.21, 95% CI 0.46 to 5.96) </p> <p>Secondary outcomes:<br/> No statistically significant differences between exercise and placebo groups in QoL (SF‐36), fatigue (fatigue severity scale) or muscle strength (manual muscle testing). </p> <p>No adverse effects reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low:<br/> Both trials had small sample sizes. 1 trial had a low risk of bias, whilst the other had high attrition (close to 30% by 3 months), no allocation concealment, and no blinding. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Multidisciplinary care</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011776-bbs2-0062" title="NgL , TalmanP , KhanF . Motor neurone disease: disability profile and service needs in an Australian cohort. International Journal of Rehabilitation Research2011;34(2):151‐9. ">Ng 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RCTs found</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: ALSFRS: Amyotrophic Lateral Sclerosis Functional Rating Scale; ALSFRS‐R: Amyotrophic Lateral Sclerosis Functional Rating Scale Revised; CI: confidence interval; MD: mean difference; QoL: quality of life; RCT: randomised controlled trial; SD: standard deviation; SEIQOL‐DW: Schedule for Evaluation of Individual Quality of Life‐Direct Weighting; SF: Short Form Health Survey; vs: versus. </p> <p>1. The review includes 20 trials, of which 7 assess cramps as an adverse event. We did not report the trials of cramps assessed as an adverse event in this overview. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Overview of reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011776.pub2/full#CD011776-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011776.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"/> </noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011776-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011776-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD011776-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011776-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"/> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011776\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011776\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011776\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011776\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011776\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=SVRJ5zHF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011776.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011776.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011776.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011776.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011776.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729799785"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011776.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729799789"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011776.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee5bb9c9ff4d2',t:'MTc0MDcyOTgwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 